/*! For license information please see main.18db2dfc.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function p(e){return e.length}function f(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,y=0,b=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function k(){return g=b>0?c(_,--b):0,v--,10===g&&(v=1,h--),g}function C(){return g=b<y?c(_,b++):0,v++,10===g&&(v=1,h++),g}function T(){return c(_,b)}function x(){return b}function F(e,t){return d(_,e,t)}function P(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function A(e){return h=v=1,y=p(_=e),b=0,[]}function E(e){return _="",e}function N(e){return s(F(b-1,O(91===e?e+2:40===e?e+1:e)))}function R(e){for(;(g=T())&&g<33;)C();return P(e)>2||P(g)>3?"":" "}function M(e,t){for(;--t&&C()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return F(e,x()+(t<6&&32==T()&&32==C()))}function O(e){for(;C();)switch(g){case e:return b;case 34:case 39:34!==e&&39!==e&&O(g);break;case 40:41===e&&O(e);break;case 92:C()}return b}function I(e,t){for(;C()&&e+g!==57&&(e+g!==84||47!==T()););return"/*"+F(t,b-1)+"*"+o(47===e?e:C())}function z(e){for(;!P(T());)C();return F(e,b)}var D="-ms-",L="-moz-",Z="-webkit-",j="comm",B="rule",V="decl",U="@keyframes";function H(e,t){for(var n="",r=f(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function W(e,t,n,r){switch(e.type){case"@import":case V:return e.return=e.return||e.value;case j:return"";case U:return e.return=e.value+"{"+H(e.children,r)+"}";case B:e.value=e.props.join(",")}return p(n=H(e.children,r))?e.return=e.value+"{"+n+"}":""}function J(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+L+e+D+e+e;case 6828:case 4268:return Z+e+D+e+e;case 6165:return Z+e+D+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+D+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+D+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+D+l(e,"shrink","negative")+e;case 5292:return Z+e+D+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+D+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(p(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?J(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,p(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===c(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+D+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+D+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+D+e+e}return e}function $(e){return E(G("",null,null,null,[""],e=A(e),0,[0],e))}function G(e,t,n,r,a,i,s,c,d){for(var f=0,h=0,v=s,y=0,b=0,g=0,_=1,w=1,S=1,F=0,P="",A=a,E=i,O=r,D=P;w;)switch(g=F,F=C()){case 40:if(108!=g&&58==D.charCodeAt(v-1)){-1!=u(D+=l(N(F),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:D+=N(F);break;case 9:case 10:case 13:case 32:D+=R(g);break;case 92:D+=M(x()-1,7);continue;case 47:switch(T()){case 42:case 47:m(K(I(C(),x()),t,n),d);break;default:D+="/"}break;case 123*_:c[f++]=p(D)*S;case 125*_:case 59:case 0:switch(F){case 0:case 125:w=0;case 59+h:b>0&&p(D)-v&&m(b>32?Q(D+";",r,n,v-1):Q(l(D," ","")+";",r,n,v-2),d);break;case 59:D+=";";default:if(m(O=q(D,t,n,f,h,a,c,P,A=[],E=[],v),i),123===F)if(0===h)G(D,t,O,O,A,i,v,c,E);else switch(y){case 100:case 109:case 115:G(e,O,O,r&&m(q(e,O,O,0,0,a,c,P,a,A=[],v),E),a,E,v,c,r?A:E);break;default:G(D,O,O,O,[""],E,0,c,E)}}f=h=b=0,_=S=1,P=D="",v=s;break;case 58:v=1+p(D),b=g;default:if(_<1)if(123==F)--_;else if(125==F&&0==_++&&125==k())continue;switch(D+=o(F),F*_){case 38:S=h>0?1:(D+="\f",-1);break;case 44:c[f++]=(p(D)-1)*S,S=1;break;case 64:45===T()&&(D+=N(C())),y=T(),h=v=p(P=D+=z(x())),F++;break;case 45:45===g&&2==p(D)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,p,m,h){for(var v=o-1,y=0===o?i:[""],b=f(y),g=0,_=0,S=0;g<r;++g)for(var k=0,C=d(e,v+1,v=a(_=u[g])),T=e;k<b;++k)(T=s(_>0?y[k]+" "+C:l(C,/&\f/g,y[k])))&&(p[S++]=T);return w(e,t,n,0===o?B:c,p,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,V,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=T(),38===r&&12===a&&(t[n]=1),!P(a);)C();return F(e,b)},X=function(e,t){return E(function(e,t){var n=-1,r=44;do{switch(P(r)){case 0:38===r&&12===T()&&(t[n]=1),e[n]+=Y(b-1,t,n);break;case 2:e[n]+=N(r);break;case 4:if(44===r){e[++n]=58===T()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=C());return e}(A(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case V:e.return=J(e.value,e.length);break;case U:return H([S(e,{value:l(e.value,"@","@"+Z)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return H([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return H([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,D+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[W,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],p=function(e){var t=f(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,H($(e?e+"{"+t.styles+"}":t.styles),p),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return f={name:t,styles:n,next:f},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function p(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return f={name:n.name,styles:n.styles,next:f},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)f={name:r.name,styles:r.styles,next:f},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=p(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=p(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=f,o=n(e);return f=a,p(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var f,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";f=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=p(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=p(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:f}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},p={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},f={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},y={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},b={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function k(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,k=void 0===u?.2:u,C=(0,a.Z)(e,g),T=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),x=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:f[200],light:f[50],dark:f[400]}:{main:f[500],light:f[300],dark:f[700]}}(n),F=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),P=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[700],light:y[500],dark:y[900]}}(n),A=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[800],light:b[500],dark:b[900]}}(n),E=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function N(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var R=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,k),S(t,"dark",c,k),t.contrastText||(t.contrastText=N(t.main)),t},M={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:R({color:T,name:"primary"}),secondary:R({color:x,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:R({color:F,name:"error"}),warning:R({color:E,name:"warning"}),info:R({color:P,name:"info"}),success:R({color:A,name:"success"}),grey:p,contrastThreshold:l,getContrastText:N,augmentColor:R,tonalOffset:k},M[n]),C)}var C=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var T={textTransform:"uppercase"},x='"Roboto", "Helvetica", "Arial", sans-serif';function F(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?x:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,p=n.fontWeightRegular,f=void 0===p?400:p,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,y=void 0===v?700:v,b=n.htmlFontSize,g=void 0===b?16:b,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,C);var k=u/14,F=w||function(e){return"".concat(e/g*k,"rem")},P=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:F(t),lineHeight:n},s===x?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},A={h1:P(d,96,1.167,-1.5),h2:P(d,60,1.2,-.5),h3:P(f,48,1.167,0),h4:P(f,34,1.235,.25),h5:P(f,24,1.334,0),h6:P(h,20,1.6,.15),subtitle1:P(f,16,1.75,.15),subtitle2:P(h,14,1.57,.1),body1:P(f,16,1.5,.15),body2:P(f,14,1.43,.15),button:P(h,14,1.75,.4,T),caption:P(f,12,1.66,.4),overline:P(f,12,2.66,1,T)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:F,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:f,fontWeightMedium:h,fontWeightBold:y},A),S,{clone:!1})}function P(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var A=["none",P(0,2,1,-1,0,1,1,0,0,1,3,0),P(0,3,1,-2,0,2,2,0,0,1,5,0),P(0,3,3,-2,0,3,4,0,0,1,8,0),P(0,2,4,-1,0,4,5,0,0,1,10,0),P(0,3,5,-1,0,5,8,0,0,1,14,0),P(0,3,5,-1,0,6,10,0,0,1,18,0),P(0,4,5,-2,0,7,10,1,0,2,16,1),P(0,5,5,-3,0,8,10,1,0,3,14,2),P(0,5,6,-3,0,9,12,1,0,3,16,2),P(0,6,6,-3,0,10,14,1,0,4,18,3),P(0,6,7,-4,0,11,15,1,0,4,20,3),P(0,7,8,-4,0,12,17,2,0,5,22,4),P(0,7,8,-4,0,13,19,2,0,5,24,4),P(0,7,9,-4,0,14,21,2,0,5,26,4),P(0,8,9,-5,0,15,22,2,0,6,28,5),P(0,8,10,-5,0,16,24,2,0,6,30,5),P(0,8,11,-5,0,17,26,2,0,6,32,5),P(0,9,11,-5,0,18,28,2,0,7,34,6),P(0,9,12,-6,0,19,29,2,0,7,36,6),P(0,10,13,-6,0,20,31,3,0,8,38,7),P(0,10,13,-6,0,21,33,3,0,8,40,7),P(0,10,14,-6,0,22,35,3,0,8,42,7),P(0,11,14,-7,0,23,36,3,0,9,44,8),P(0,11,15,-7,0,24,38,3,0,9,46,8)],E=["duration","easing","delay"],N={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},R={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function M(e){return"".concat(Math.round(e),"ms")}function O(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function I(e){var t=(0,r.Z)({},N,e.easing),n=(0,r.Z)({},R,e.duration);return(0,r.Z)({getAutoHeightDuration:O,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,E);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:M(i)," ").concat(l," ").concat("string"===typeof c?c:M(c))})).join(",")}},e,{easing:t,duration:n})}var z={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},D=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,p=void 0===d?{}:d,f=e.typography,m=void 0===f?{}:f,h=(0,a.Z)(e,D);if(e.vars)throw new Error((0,o.Z)(18));var v=k(c),y=(0,s.Z)(e),b=(0,i.Z)(y,{mixins:u(y.breakpoints,n),palette:v,shadows:A.slice(),typography:F(v,m),transitions:I(p),zIndex:(0,r.Z)({},z)});b=(0,i.Z)(b,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,i.Z)(e,t)}),b)}var Z=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return k},isMuiElement:function(){return C},ownerDocument:function(){return x},ownerWindow:function(){return F},requirePropFactory:function(){return P},setRef:function(){return A},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return E},unstable_useId:function(){return O},unsupportedProp:function(){return I},useControlled:function(){return z},useEventCallback:function(){return D.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),p=n(5513),f=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),y=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],b=(0,f.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,p,f,m,h,v,y,b=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=b.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=b.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=b.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=b.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=b.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(p=(b.vars||b).palette)||null==(f=p[g.color])?void 0:f.main)?d:{action:null==(m=(b.vars||b).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(b.vars||b).palette)||null==(y=v.action)?void 0:y.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,p.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,f=n.component,m=void 0===f?"svg":f,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,k=void 0!==S&&S,C=n.titleAccess,T=n.viewBox,x=void 0===T?"0 0 24 24":T,F=(0,u.Z)(n,y),P=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:k,viewBox:x}),A={};k||(A.viewBox=x);var E=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(P);return(0,v.jsxs)(b,(0,i.Z)({as:m,className:(0,c.Z)(E.root,o),focusable:"false",color:w,"aria-hidden":!C||void 0,role:C?"img":void 0,ref:t},A,F,{ownerState:P,children:[r,C?(0,v.jsx)("title",{children:C}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var k=function(e,t){return function(){return null}};var C=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function T(e){return e&&e.ownerDocument||document}var x=T;var F=function(e){return T(e).defaultView||window};var P=function(e,t){return function(){return null}},A=n(2971).Z,E=n(5721).Z,N=n(885),R=0;var M=l.useId;var O=function(e){if(void 0!==M){var t=M();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,N.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(R+=1))}),[r]),o}(e)};var I=function(e,t,n,r,a){return null};var z=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,N.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},D=n(6702),L=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var p=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),p=s,f=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?p:f},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},y=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var p=h(t,n,s),f=p||m(d),y=!f("as");return function(){var b=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==b[0]||void 0===b[0].raw)g.push.apply(g,b);else{0,g.push(b[0][0]);for(var _=b.length,w=1;w<_;w++)g.push(b[w],b[0][w])}var S=(0,l.w)((function(e,t,n){var a=y&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var b in h={},e)h[b]=e[b];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=y&&void 0===p?m(a):f,S={};for(var k in e)y&&"as"===k||w(k)&&(S[k]=e[k]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=p,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},b=y.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){b[e]=b(e)}));var g=b;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return C},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function p(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var f=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function y(e){return 0===Object.keys(e).length}function b(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=p(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[p(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var k=(0,l.Z)();function C(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?k:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,p=e.styleFunctionSx,C=void 0===p?f.Z:p,T=function(e){var t=y(e.theme)?n:e.theme;return C((0,i.Z)({},e,{theme:t}))};return T.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,p=t.slot,f=t.skipVariantsResolver,k=t.skipSx,C=t.overridesResolver,x=(0,o.Z)(t,m),F=void 0!==f?f:p&&"Root"!==p||!1,P=k||!1;var A=S;"Root"===p?A=u:p?A=d:b(e)&&(A=void 0);var E=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:A,label:l},x)),N=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:y(r)?n:r},a))}:e})):[],d=e;c&&C&&u.push((function(e){var t=y(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),C(e,o)}return null})),c&&!F&&u.push((function(e){var t=y(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),P||u.push(T);var p=u.length-s.length;if(Array.isArray(e)&&p>0){var f=new Array(p).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(f))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(f))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:y(r)?n:r},a))});var m=E.apply(void 0,[d].concat((0,r.Z)(u)));return m};return E.withConfig&&(N.withConfig=E.withConfig),N}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),p=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),f=Object.keys(p);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=f.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[f[r]]?n[f[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:f,values:p,up:m,down:h,between:v,only:function(e){return f.indexOf(e)+1<f.length?v(e,f[f.indexOf(e)+1]):m(e)},not:function(e){var t=f.indexOf(e);return 0===t?m(f[1]):t===f.length-1?h(f[t]):v(e,f[f.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var p=["breakpoints","palette","spacing","shape"];var f=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,f=e.shape,m=void 0===f?{}:f,h=(0,a.Z)(e,p),v=l(n),y=d(c),b=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:y,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,o.Z)(e,t)}),b)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return G}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,p,f,m,h,v,y,b,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),k=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["gap"];var C=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["columnGap"];var T=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["rowGap"];var x=o(k,C,T,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),F=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),P=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),A=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function E(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var N=(0,r.Z)({prop:"width",transform:E}),R=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||E(t)}}))}return null};R.filterProps=["maxWidth"];var M=(0,r.Z)({prop:"minWidth",transform:E}),O=(0,r.Z)({prop:"height",transform:E}),I=(0,r.Z)({prop:"maxHeight",transform:E}),z=(0,r.Z)({prop:"minHeight",transform:E}),D=((0,r.Z)({prop:"size",cssProperty:"width",transform:E}),(0,r.Z)({prop:"size",cssProperty:"height",transform:E}),o(N,R,M,O,I,z,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),V=(0,r.Z)({prop:"letterSpacing"}),U=(0,r.Z)({prop:"textTransform"}),H=(0,r.Z)({prop:"lineHeight"}),W=(0,r.Z)({prop:"textAlign"}),J=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,Z,j,B,V,H,W,U),$={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:x.filterProps,positions:F.filterProps,palette:P.filterProps,shadows:A.filterProps,sizing:D.filterProps,spacing:i.ZP.filterProps,typography:J.filterProps},G={borders:_,display:w,flexbox:S,grid:x,positions:F,palette:P,shadows:A,sizing:D,spacing:i.ZP,typography:J},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=G[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],p=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],f=[].concat(d,p);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function y(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function b(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return y(e,t,r,n)})).reduce(i.Z,{})}function g(e){return b(e,d)}function _(e){return b(e,p)}function w(e){return b(e,f)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=p,w.propTypes={},w.filterProps=f;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,p=void 0===d?{}:d;if(!c)return null;function f(e){var o=e;if("function"===typeof e)o=e(p);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(p.breakpoints),d=Object.keys(c),f=c;return Object.keys(o).forEach((function(e){var c=l(o[e],p);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])f=(0,a.Z)(f,n(e,c,p));else{var d=(0,i.k9)({theme:p},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?f[e]=u({sx:c,theme:p}):f=(0,a.Z)(f,d)}else f=(0,a.Z)(f,n(e,c,p))})),(0,i.L7)(d,f)}return Array.isArray(c)?c.map(f):f(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var p=t[i-1];return i>1&&"string"===typeof p.value&&(p.added||p.removed)&&e.equals("",p.value)&&(t[i-2].value+=p.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,p=[{newPos:-1,components:[]}],f=this.extractCommon(p[0],t,e,0);if(p[0].newPos+1>=l&&f+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=p[a-1],f=p[a+1],m=(f?f.newPos:0)-a;d&&(p[a-1]=void 0);var h=d&&d.newPos+1<l,v=f&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<f.newPos?(o=r(f),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));p[a]=o}else p[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var p=new t;function f(e,t,n){return p.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return p.diff(e,t,r)}p.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var y=new t;function b(e,t,n){return y.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||k()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function k(){throw new TypeError("Invalid attempt to spread non-iterable instance")}y.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var C=Object.prototype.toString,T=new t;function x(e,t,n){return T.diff(e,t,n)}function F(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===C.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=F(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=F(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}T.useLongestToken=!0,T.tokenize=p.tokenize,T.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(F(e,null,null,a),a,"  ")},T.equals=function(e,n){return t.prototype.equals.call(T,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var P=new t;function A(e,t,n){return P.diff(e,t,n)}function E(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function N(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function R(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=E(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,p=0;function f(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,y=0,b=p+h.oldStart-1,g=N(b,d,v);void 0!==y;y=g())if(f(h,b+y)){h.offset=p+=y;break}if(void 0===y)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],k=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,k<0&&(k=0);for(var C=0;C<S.lines.length;C++){var T=S.lines[C],x=T.length>0?T[0]:" ",F=T.length>0?T.substr(1):T,P=S.linedelimiters[C];if(" "===x)k++;else if("-"===x)o.splice(k,1),i.splice(k,1);else if("+"===x)o.splice(k,0,F),i.splice(k,0,P),k++;else if("\\"===x){var A=S.lines[C-1]?S.lines[C-1][0]:null;"+"===A?r=!0:"-"===A&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var R=0;R<o.length-1;R++)o[R]=o[R]+i[R];return o.join("")}function M(e,t){"string"===typeof e&&(e=E(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=R(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function O(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=f(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,p=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var f=s[e-1];c=m,d=h,f&&(p=i.context>0?l(f.lines.slice(-i.context)):[],c-=p.length,d-=p.length)}(o=p).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=p).push.apply(v,_(l(a)))}else{var y,b=Math.min(a.length,i.context);(y=p).push.apply(y,_(l(a.slice(0,b))));var g={oldStart:c,oldLines:m-c+b,newStart:d,newLines:h-d+b,lines:p};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),k=0==a.length&&p.length>g.oldLines;!w&&k&&p.splice(g.oldLines,0,"\\ No newline at end of file"),(w||k)&&S||p.push("\\ No newline at end of file")}u.push(g),c=0,d=0,p=[]}m+=a.length,h+=a.length}},y=0;y<s.length;y++)v(y);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function I(e,t,n,r,a,o,i){var s=O(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function z(e,t,n,r,a,o){return I(e,e,t,n,r,a,o)}function D(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(V(e)?V(t)?(r.oldFileName=U(r,e.oldFileName,t.oldFileName),r.newFileName=U(r,e.newFileName,t.newFileName),r.oldHeader=U(r,e.oldHeader,t.oldHeader),r.newHeader=U(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(H(l,u))r.hunks.push(W(l,i)),a++,s+=l.newLines-l.oldLines;else if(H(u,l))r.hunks.push(W(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};J(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return E(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return O(void 0,void 0,t,e)}return e}function V(e){return e.newFileName&&e.newFileName!==e.oldFileName}function U(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function H(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function W(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function J(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(Y(i)))}else"-"===s[0]&&" "===l[0]?G(e,o,i):"-"===l[0]&&" "===s[0]?G(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else $(e,o,i)}Q(e,o),Q(e,i),Z(e)}function $(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(D(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function G(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}P.tokenize=function(e){return e.slice()},P.join=P.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=f,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=b,e.diffJson=x,e.diffArrays=A,e.structuredPatch=O,e.createTwoFilesPatch=I,e.createPatch=z,e.applyPatch=R,e.applyPatches=M,e.parsePatch=E,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=F,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return D},cx:function(){return R},flush:function(){return E},getRegisteredStyles:function(){return O},hydrate:function(){return N},injectGlobal:function(){return I},keyframes:function(){return z},merge:function(){return M},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,p){for(var f,m,h,v,_,S=0,k=0,C=0,T=0,x=0,R=0,O=h=f=0,z=0,D=0,L=0,Z=0,j=l.length,B=j-1,V="",U="",H="",W="";z<j;){if(m=l.charCodeAt(z),z===B&&0!==k+T+C+S&&(0!==k&&(m=47===k?10:47),T=C=S=0,j++,B++),0===k+T+C+S){if(z===B&&(0<D&&(V=V.replace(d,"")),0<V.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:V+=l.charAt(z)}m=59}switch(m){case 123:for(f=(V=V.trim()).charCodeAt(0),h=1,Z=++z;z<j;){switch(m=l.charCodeAt(z)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(z+1)){case 42:case 47:e:{for(O=z+1;O<B;++O)switch(l.charCodeAt(O)){case 47:if(42===m&&42===l.charCodeAt(O-1)&&z+2!==O){z=O+1;break e}break;case 10:if(47===m){z=O+1;break e}}z=O}}break;case 91:m++;case 40:m++;case 34:case 39:for(;z++<B&&l.charCodeAt(z)!==m;);}if(0===h)break;z++}if(h=l.substring(Z,z),0===f&&(f=(V=V.replace(c,"").trim()).charCodeAt(0)),64===f){switch(0<D&&(V=V.replace(d,"")),m=V.charCodeAt(1)){case 100:case 109:case 115:case 45:D=r;break;default:D=N}if(Z=(h=t(r,D,h,m,p+1)).length,0<M&&(_=s(3,h,D=n(N,V,L),r,P,F,Z,m,p,u),V=D.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:V=V.replace(w,i);case 100:case 109:case 45:h=V+"{"+h+"}";break;case 107:h=(V=V.replace(y,"$1 $2"))+"{"+h+"}",h=1===E||2===E&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=V+h,112===u&&(U+=h,h="")}else h=""}else h=t(r,n(r,V,L),h,u,p+1);H+=h,h=L=D=O=f=0,V="",m=l.charCodeAt(++z);break;case 125:case 59:if(1<(Z=(V=(0<D?V.replace(d,""):V).trim()).length))switch(0===O&&(f=V.charCodeAt(0),45===f||96<f&&123>f)&&(Z=(V=V.replace(" ",":")).length),0<M&&void 0!==(_=s(1,V,r,e,P,F,U.length,u,p,u))&&0===(Z=(V=_.trim()).length)&&(V="\0\0"),f=V.charCodeAt(0),m=V.charCodeAt(1),f){case 0:break;case 64:if(105===m||99===m){W+=V+l.charAt(z);break}default:58!==V.charCodeAt(Z-1)&&(U+=a(V,f,m,V.charCodeAt(2)))}L=D=O=f=0,V="",m=l.charCodeAt(++z)}}switch(m){case 13:case 10:47===k?k=0:0===1+f&&107!==u&&0<V.length&&(D=1,V+="\0"),0<M*I&&s(0,V,r,e,P,F,U.length,u,p,u),F=1,P++;break;case 59:case 125:if(0===k+T+C+S){F++;break}default:switch(F++,v=l.charAt(z),m){case 9:case 32:if(0===T+S+k)switch(x){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===T+k+S&&(D=L=1,v="\f"+v);break;case 108:if(0===T+k+S+A&&0<O)switch(z-O){case 2:112===x&&58===l.charCodeAt(z-3)&&(A=x);case 8:111===R&&(A=R)}break;case 58:0===T+k+S&&(O=z);break;case 44:0===k+C+T+S&&(D=1,v+="\r");break;case 34:case 39:0===k&&(T=T===m?0:0===T?m:T);break;case 91:0===T+k+C&&S++;break;case 93:0===T+k+C&&S--;break;case 41:0===T+k+S&&C--;break;case 40:if(0===T+k+S){if(0===f)if(2*x+3*R===533);else f=1;C++}break;case 64:0===k+C+T+S+O+h&&(h=1);break;case 42:case 47:if(!(0<T+S+C))switch(k){case 0:switch(2*m+3*l.charCodeAt(z+1)){case 235:k=47;break;case 220:Z=z,k=42}break;case 42:47===m&&42===x&&Z+2!==z&&(33===l.charCodeAt(Z+2)&&(U+=l.substring(Z,z+1)),v="",k=0)}}0===k&&(V+=v)}R=x,x=m,z++}if(0<(Z=U.length)){if(D=r,0<M&&(void 0!==(_=s(2,U,D,e,P,F,Z,u,p,u))&&0===(U=_).length))return W+U+H;if(U=D.join(",")+"{"+U+"}",0!==E*A){switch(2!==E||o(U,2)||(A=0),A){case 111:U=U.replace(g,":-moz-$1")+U;break;case 112:U=U.replace(b,"::-webkit-input-$1")+U.replace(b,"::-moz-$1")+U.replace(b,":-ms-input-$1")+U}A=0}}return W+U+H}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===E||2===E&&o(l,1)?"-webkit-"+l+l:l}if(0===E||2===E&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(x,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return f.test(i)?i.replace(p,":-webkit-")+i.replace(p,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(k,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(k,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===T.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),O(2!==t?r:r.replace(C,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,p=0,f=t;p<M;++p)switch(d=R[p].call(u,e,f,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:f=d}if(f!==t)return f}function l(e){return void 0!==(e=e.prefix)&&(O=null,e?"function"!==typeof e?E=1:(E=2,O=e):E=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<M){var a=s(-1,n,r,r,P,F,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(N,r,n,0,0);return 0<M&&(void 0!==(a=s(-2,o,r,r,P,F,o.length,0,0,0))&&(o=a)),"",A=0,F=P=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,p=/: */g,f=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,y=/@(k\w+)\s*(\S*)\s*/,b=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,k=/-self|flex-/g,C=/[^]*?(:[rp][el]a[\w-]+)[^]*/,T=/stretch|:\s*\w+\-(?:conte|avail)/,x=/([^-])(image-set\()/,F=1,P=1,A=0,E=1,N=[],R=[],M=0,O=null,I=0;return u.use=function e(t){switch(t){case void 0:case null:M=R.length=0;break;default:if("function"===typeof t)R[M++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else I=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,p){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===p?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(p.inserted[a]=!0)};var p={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return p};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var p=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},f=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},y=p((function(e){return h(e)?e:e.replace(f,"-$&").toLowerCase()})),b=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=y(o)+":"+b(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=y(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=y(o)+":"+b(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function k(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var C=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function T(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function x(e,t,n){var r=[],a=k(e,r,n);return r.length<2?n:a+t(r)}var F=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},P=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return C(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return x(t.registered,n,F(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);T(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return T(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:k.bind(null,t.registered),merge:x.bind(null,t.registered,n)}},A=P(),E=A.flush,N=A.hydrate,R=A.cx,M=A.merge,O=A.getRegisteredStyles,I=A.injectGlobal,z=A.keyframes,D=A.css,L=A.sheet,Z=A.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=f(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var y=i[v];if(!o[y]&&(!r||!r[y])&&(!h||!h[y])&&(!s||!s[y])){var b=p(n,y);try{u(t,y,b)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,p=n?Symbol.for("react.forward_ref"):60112,f=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,y=n?Symbol.for("react.block"):60121,b=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case f:return e;default:switch(e=e&&e.$$typeof){case u:case p:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=p,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=f,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===p},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===f},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===f||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===p||e.$$typeof===b||e.$$typeof===g||e.$$typeof===_||e.$$typeof===y)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),p="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:p,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},p=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},f=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return f(e,t,n,r);if(i(e))return p(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),p=c,f=c,m=[],h=0,v=[],y=[],b=function e(t,a,s,c,m){return u(t).map((function(t,b){var g={},_={};if(!(y.includes(a+"-"+b)||m&&0!==b)){if(s||c)if(v.includes(h)||v.push(h),c){f+=1,g.lineNumber=f,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[b]){var S=e(w.value,a,!0,!1,!0)[0].right,k=S.value,C=S.lineNumber,T=S.type;if(y.push(a+1+"-"+b),_.lineNumber=C,_.type=T,n)_.value=k;else{var x=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,k,r);_.value=x.right,g.value=x.left}}}else p+=1,_.lineNumber=p,_.type=o.ADDED,_.value=t;else f+=1,p+=1,g.lineNumber=f,g.type=o.DEFAULT,g.value=t,_.lineNumber=p,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,b(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var p=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,p,f,m,h=r+"-"+e,v=u+"-"+l,y=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),b=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=b,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=y,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=b,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=y,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=b,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=y,p))},a.createElement("pre",null,b&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=b,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=y,f))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),p=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),f=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=f,s))}),f?a.createElement(a.Fragment,null,a.createElement("td",null),p):a.createElement(a.Fragment,null,p,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,p=c.diffLines,f=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=p[0],i=r-t;if(n.props.showDiffOnly&&(i===-f&&(m=[],p.shift()),e.left.type===s.DiffType.DEFAULT&&(i>f||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===f&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var p=n.renderDiff(),f=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?f:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:f,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,p))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=p},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var p=e.variables,f=void 0===p?{}:p,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},f.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},f.dark||{})},v=t?h.dark:h.light,y=o.css({width:"100%",label:"content"}),b=o.css(((n={})["."+y]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),k=o.css({color:v.gutterColor,label:"line-number"}),C=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+k]={color:v.removedGutterColor},s.label="diff-removed",s)),T=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+k]={color:v.addedGutterColor},l.label="diff-added",l)),x=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),F=o.css({background:v.wordAddedBackground,label:"word-added"}),P=o.css({background:v.wordRemovedBackground,label:"word-removed"}),A=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),E=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),N=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),R=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+T]={pre:{color:v.addedColor}},u["&."+C]={pre:{color:v.removedColor}},u)),M=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+F+", ."+P]={backgroundColor:"initial"},c)),O=o.css({label:"highlighted-gutter"}),I=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+T]={background:v.addedGutterBackground},d["&."+C]={background:v.removedGutterBackground},d["&."+O]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),z=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),D={diffContainer:g,diffRemoved:C,diffAdded:T,splitView:b,marker:R,highlightedGutter:O,highlightedLine:M,gutter:I,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:x,wordAdded:F,wordRemoved:P,codeFoldGutter:A,codeFold:E,emptyGutter:z,emptyLine:N,lineNumber:k,contentText:w,content:y,codeFoldContent:_,titleBlock:S},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(D).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(D[t],L[t]):D[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,p=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,f={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var y=/[\-:]([a-z])/g;function b(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(f,e)&&(p.test(e)?m[e]=!0:(f[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),k=Symbol.for("react.fragment"),C=Symbol.for("react.strict_mode"),T=Symbol.for("react.profiler"),x=Symbol.for("react.provider"),F=Symbol.for("react.context"),P=Symbol.for("react.forward_ref"),A=Symbol.for("react.suspense"),E=Symbol.for("react.suspense_list"),N=Symbol.for("react.memo"),R=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var M=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var O=Symbol.iterator;function I(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=O&&e[O]||e["@@iterator"])?e:null}var z,D=Object.assign;function L(e){if(void 0===z)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);z=t&&t[1]||""}return"\n"+z+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function B(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function V(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case k:return"Fragment";case S:return"Portal";case T:return"Profiler";case C:return"StrictMode";case A:return"Suspense";case E:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case F:return(e.displayName||"Context")+".Consumer";case x:return(e._context.displayName||"Context")+".Provider";case P:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case N:return null!==(t=e.displayName||null)?t:V(e.type)||"Memo";case R:t=e._payload,e=e._init;try{return V(e(t))}catch(n){}}return null}function U(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return V(t);case 8:return t===C?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function H(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function W(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function J(e){e._valueTracker||(e._valueTracker=function(e){var t=W(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=W(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function G(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return D({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=H(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=H(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,H(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&G(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+H(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return D({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:H(n)}}function oe(e,t){var n=H(t.value),r=H(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function pe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var fe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||fe.hasOwnProperty(e)&&fe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(fe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),fe[t]=fe[e]}))}));var ye=D({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function be(e,t){if(t){if(ye[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,ke=null,Ce=null;function Te(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function xe(e){ke?Ce?Ce.push(e):Ce=[e]:ke=e}function Fe(){if(ke){var e=ke,t=Ce;if(Ce=ke=null,Te(e),t)for(e=0;e<t.length;e++)Te(t[e])}}function Pe(e,t){return e(t)}function Ae(){}var Ee=!1;function Ne(e,t,n){if(Ee)return e(t,n);Ee=!0;try{return Pe(e,t,n)}finally{Ee=!1,(null!==ke||null!==Ce)&&(Ae(),Fe())}}function Re(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Me=!1;if(c)try{var Oe={};Object.defineProperty(Oe,"passive",{get:function(){Me=!0}}),window.addEventListener("test",Oe,Oe),window.removeEventListener("test",Oe,Oe)}catch(ce){Me=!1}function Ie(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var ze=!1,De=null,Le=!1,Ze=null,je={onError:function(e){ze=!0,De=e}};function Be(e,t,n,r,a,o,i,s,l){ze=!1,De=null,Ie.apply(je,arguments)}function Ve(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Ue(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function He(e){if(Ve(e)!==e)throw Error(o(188))}function We(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=Ve(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return He(a),e;if(i===r)return He(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?Je(e):null}function Je(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Je(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,Ge=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function pt(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function ft(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function yt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function bt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,kt,Ct,Tt,xt=!1,Ft=[],Pt=null,At=null,Et=null,Nt=new Map,Rt=new Map,Mt=[],Ot="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function It(e,t){switch(e){case"focusin":case"focusout":Pt=null;break;case"dragenter":case"dragleave":At=null;break;case"mouseover":case"mouseout":Et=null;break;case"pointerover":case"pointerout":Nt.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Rt.delete(t.pointerId)}}function zt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function Dt(e){var t=ba(e.target);if(null!==t){var n=Ve(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Ue(n)))return e.blockedOn=t,void Tt(e.priority,(function(){kt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){Lt(e)&&n.delete(t)}function jt(){xt=!1,null!==Pt&&Lt(Pt)&&(Pt=null),null!==At&&Lt(At)&&(At=null),null!==Et&&Lt(Et)&&(Et=null),Nt.forEach(Zt),Rt.forEach(Zt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,xt||(xt=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Vt(e){function t(t){return Bt(t,e)}if(0<Ft.length){Bt(Ft[0],e);for(var n=1;n<Ft.length;n++){var r=Ft[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Pt&&Bt(Pt,e),null!==At&&Bt(At,e),null!==Et&&Bt(Et,e),Nt.forEach(t),Rt.forEach(t),n=0;n<Mt.length;n++)(r=Mt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Mt.length&&null===(n=Mt[0]).blockedOn;)Dt(n),null===n.blockedOn&&Mt.shift()}var Ut=_.ReactCurrentBatchConfig,Ht=!0;function Wt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function Jt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function $t(e,t,n,r){if(Ht){var a=qt(e,t,n,r);if(null===a)Hr(e,t,r,Gt,n),It(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Pt=zt(Pt,e,t,n,r,a),!0;case"dragenter":return At=zt(At,e,t,n,r,a),!0;case"mouseover":return Et=zt(Et,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Nt.set(o,zt(Nt.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Rt.set(o,zt(Rt.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(It(e,r),4&t&&-1<Ot.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Hr(e,t,r,Gt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Hr(e,t,r,null,n)}}var Gt=null;function qt(e,t,n,r){if(Gt=null,null!==(e=ba(e=we(r))))if(null===(t=Ve(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Ue(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Gt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return D(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=D({},un,{view:0,detail:0}),pn=an(dn),fn=D({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Tn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(fn),hn=an(D({},fn,{dataTransfer:0})),vn=an(D({},dn,{relatedTarget:0})),yn=an(D({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),bn=D({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(bn),_n=an(D({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},kn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Cn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=kn[e])&&!!t[e]}function Tn(){return Cn}var xn=D({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Tn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),Fn=an(xn),Pn=an(D({},fn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),An=an(D({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Tn})),En=an(D({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),Nn=D({},fn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Rn=an(Nn),Mn=[9,13,27,32],On=c&&"CompositionEvent"in window,In=null;c&&"documentMode"in document&&(In=document.documentMode);var zn=c&&"TextEvent"in window&&!In,Dn=c&&(!On||In&&8<In&&11>=In),Ln=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==Mn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Vn=!1;var Un={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Hn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Un[e.type]:"textarea"===t}function Wn(e,t,n,r){xe(r),0<(t=Jr(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Jn=null,$n=null;function Gn(e){Lr(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Yn;if(c){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Jn&&(Jn.detachEvent("onpropertychange",nr),$n=Jn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Wn(t,$n,e,we(e)),Ne(Gn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Jn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function pr(){for(var e=window,t=G();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=G((e=t.contentWindow).document)}return t}function fr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=pr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&fr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,yr=null,br=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==G(r)||("selectionStart"in(r=vr)&&fr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},br&&lr(br,r)||(br=r,0<(r=Jr(yr,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},kr={},Cr={};function Tr(e){if(kr[e])return kr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Cr)return kr[e]=n[t];return e}c&&(Cr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var xr=Tr("animationend"),Fr=Tr("animationiteration"),Pr=Tr("animationstart"),Ar=Tr("transitionend"),Er=new Map,Nr="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Rr(e,t){Er.set(e,t),l(t,[e])}for(var Mr=0;Mr<Nr.length;Mr++){var Or=Nr[Mr];Rr(Or.toLowerCase(),"on"+(Or[0].toUpperCase()+Or.slice(1)))}Rr(xr,"onAnimationEnd"),Rr(Fr,"onAnimationIteration"),Rr(Pr,"onAnimationStart"),Rr("dblclick","onDoubleClick"),Rr("focusin","onFocus"),Rr("focusout","onBlur"),Rr(Ar,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Ir="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),zr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Ir));function Dr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(Be.apply(this,arguments),ze){if(!ze)throw Error(o(198));var c=De;ze=!1,De=null,Le||(Le=!0,Ze=c)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;Dr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;Dr(a,s,u),o=l}}}if(Le)throw e=Ze,Le=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Ur(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Ur(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Vr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(zr.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,jr("selectionchange",!1,t))}}function Ur(e,t,n,r){switch(Kt(t)){case 1:var a=Wt;break;case 4:a=Jt;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Me||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Hr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ba(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Ne((function(){var r=o,a=we(n),i=[];e:{var s=Er.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=Fn;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=An;break;case xr:case Fr:case Pr:l=yn;break;case Ar:l=En;break;case"scroll":l=pn;break;case"wheel":l=Rn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=Pn}var c=0!==(4&t),d=!c&&"scroll"===e,p=c?null!==s?s+"Capture":null:s;c=[];for(var f,m=r;null!==m;){var h=(f=m).stateNode;if(5===f.tag&&null!==h&&(f=h,null!==p&&(null!=(h=Re(m,p))&&c.push(Wr(m,h,f)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ba(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ba(u):null)&&(u!==(d=Ve(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",p="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=Pn,h="onPointerLeave",p="onPointerEnter",m="pointer"),d=null==l?s:_a(l),f=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=f,h=null,ba(a)===r&&((c=new c(p,m+"enter",u,n,a)).target=f,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(p=u,m=0,f=c=l;f;f=$r(f))m++;for(f=0,h=p;h;h=$r(h))f++;for(;0<m-f;)c=$r(c),m--;for(;0<f-m;)p=$r(p),f--;for(;m--;){if(c===p||null!==p&&c===p.alternate)break e;c=$r(c),p=$r(p)}c=null}else c=null;null!==l&&Gr(i,s,l,c,!1),null!==u&&null!==d&&Gr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Hn(s))if(Qn)v=ir;else{v=ar;var y=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Wn(i,v,n,a):(y&&y(e,s,r),"focusout"===e&&(y=s._wrapperState)&&y.controlled&&"number"===s.type&&ee(s,"number",s.value)),y=r?_a(r):window,e){case"focusin":(Hn(y)||"true"===y.contentEditable)&&(vr=y,yr=r,br=null);break;case"focusout":br=yr=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var b;if(On)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Vn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(Dn&&"ko"!==n.locale&&(Vn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Vn&&(b=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Vn=!0)),0<(y=Jr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:y}),b?g.data=b:null!==(b=Bn(n))&&(g.data=b))),(b=zn?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(Zn=!0,Ln);case"textInput":return(e=t.data)===Ln&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Vn)return"compositionend"===e||!On&&jn(e,t)?(e=en(),Xt=Yt=Qt=null,Vn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Dn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Jr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=b))}Lr(i,t)}))}function Wr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Jr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Re(e,n))&&r.unshift(Wr(e,o,a)),null!=(o=Re(e,t))&&r.push(Wr(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Gr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Re(n,o))&&i.unshift(Wr(n,l,s)):a||null!=(l=Re(n,o))&&i.push(Wr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Vt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Vt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),pa="__reactFiber$"+da,fa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ya="__reactHandles$"+da;function ba(e){var t=e[pa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[pa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[pa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[pa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[fa]||null}var Sa=[],ka=-1;function Ca(e){return{current:e}}function Ta(e){0>ka||(e.current=Sa[ka],Sa[ka]=null,ka--)}function xa(e,t){ka++,Sa[ka]=e.current,e.current=t}var Fa={},Pa=Ca(Fa),Aa=Ca(!1),Ea=Fa;function Na(e,t){var n=e.type.contextTypes;if(!n)return Fa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Ra(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Ma(){Ta(Aa),Ta(Pa)}function Oa(e,t,n){if(Pa.current!==Fa)throw Error(o(168));xa(Pa,t),xa(Aa,n)}function Ia(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,U(e)||"Unknown",a));return D({},n,r)}function za(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Fa,Ea=Pa.current,xa(Pa,e),xa(Aa,Aa.current),!0}function Da(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Ia(e,t,Ea),r.__reactInternalMemoizedMergedChildContext=e,Ta(Aa),Ta(Pa),xa(Pa,e)):Ta(Aa),xa(Aa,n)}var La=null,Za=!1,ja=!1;function Ba(e){null===La?La=[e]:La.push(e)}function Va(){if(!ja&&null!==La){ja=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Za=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),$e(Xe,Va),a}finally{gt=t,ja=!1}}return null}var Ua=[],Ha=0,Wa=null,Ja=0,$a=[],Ga=0,qa=null,Ka=1,Qa="";function Ya(e,t){Ua[Ha++]=Ja,Ua[Ha++]=Wa,Wa=e,Ja=t}function Xa(e,t,n){$a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Wa;)Wa=Ua[--Ha],Ua[Ha]=null,Ja=Ua[--Ha],Ua[Ha]=null;for(;e===qa;)qa=$a[--Ga],$a[Ga]=null,Qa=$a[--Ga],$a[Ga]=null,Ka=$a[--Ga],$a[Ga]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Nu(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Nu(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function po(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw fo(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function fo(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function yo(e,t){if(e&&e.defaultProps){for(var n in t=D({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var bo=Ca(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function ko(e){var t=bo.current;Ta(bo),e._currentValue=t}function Co(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function To(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function xo(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var Fo=null;function Po(e){null===Fo?Fo=[e]:Fo.push(e)}function Ao(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Po(t)):(n.next=a.next,a.next=n),t.interleaved=n,Eo(e,r)}function Eo(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var No=!1;function Ro(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Mo(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Oo(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Io(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Pl)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Eo(e,n)}return null===(a=r.interleaved)?(t.next=t,Po(r)):(t.next=a.next,a.next=t),r.interleaved=t,Eo(e,n)}function zo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}function Do(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;No=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var p=s.lane,f=s.eventTime;if((r&p)===p){null!==c&&(c=c.next={eventTime:f,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(p=t,f=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(f,d,p);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(p="function"===typeof(m=h.payload)?m.call(f,d,p):m)||void 0===p)break e;d=D({},d,p);break e;case 2:No=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(p=a.effects)?a.effects=[s]:p.push(s))}else f={eventTime:f,lane:p,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=f,l=d):c=c.next=f,i|=p;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(p=s).next,p.next=null,a.lastBaseUpdate=p,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);zl|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:D({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Vo={isMounted:function(e){return!!(e=e._reactInternals)&&Ve(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Oo(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Io(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Oo(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Io(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Oo(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Io(e,a,r))&&(nu(t,e,r,n),zo(t,e,r))}};function Uo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Ho(e,t,n){var r=!1,a=Fa,o=t.contextType;return"object"===typeof o&&null!==o?o=xo(o):(a=Ra(t)?Ea:Pa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Na(e,a):Fa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Vo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Wo(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Vo.enqueueReplaceState(t,t.state,null)}function Jo(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,Ro(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=xo(o):(o=Ra(t)?Ea:Pa.current,a.context=Na(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Vo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Go(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Mu(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Du(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===k?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===R&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Ou(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lu(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Iu(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function p(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Du(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Ou(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case S:return(t=Lu(t,e.mode,n)).return=e,t;case R:return p(e,(0,t._init)(t._payload),n)}if(te(t)||I(t))return(t=Iu(t,e.mode,n,null)).return=e,t;Go(e,t)}return null}function f(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case R:return f(e,t,(a=n._init)(n._payload),r)}if(te(n)||I(n))return null!==a?null:d(e,t,n,r,null);Go(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case R:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||I(r))return d(t,e=e.get(n)||null,r,a,null);Go(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var y=f(a,d,s[h],l);if(null===y){null===d&&(d=v);break}e&&d&&null===y.alternate&&t(a,d),o=i(y,o,h),null===c?u=y:c.sibling=y,c=y,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=p(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Ya(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),u}function v(a,s,l,u){var c=I(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,y=null,b=l.next();null!==h&&!b.done;v++,b=l.next()){h.index>v?(y=h,h=null):y=h.sibling;var g=f(a,h,b.value,u);if(null===g){null===h&&(h=y);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=y}if(b.done)return n(a,h),ao&&Ya(a,v),c;if(null===h){for(;!b.done;v++,b=l.next())null!==(b=p(a,b.value,u))&&(s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return ao&&Ya(a,v),c}for(h=r(a,h);!b.done;v++,b=l.next())null!==(b=m(h,a,v,b.value,u))&&(e&&null!==b.alternate&&h.delete(null===b.key?v:b.key),s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===k&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===k){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===R&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=$o(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===k?((o=Iu(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Ou(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lu(i,r.mode,l)).return=r,r=o}return s(r);case R:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(I(i))return v(r,o,i,l);Go(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=Du(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=Ca(Xo),ti=Ca(Xo),ni=Ca(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(xa(ni,t),xa(ti,e),xa(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Ta(ei),xa(ei,t)}function oi(){Ta(ei),Ta(ti),Ta(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(xa(ti,e),xa(ei,n))}function si(e){ti.current===e&&(Ta(ei),Ta(ti))}var li=Ca(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var pi=_.ReactCurrentDispatcher,fi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,yi=null,bi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function ki(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ci(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,pi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,yi=vi=null,t.updateQueue=null,pi.current=us,e=n(r,a)}while(gi)}if(pi.current=is,t=null!==vi&&null!==vi.next,mi=0,yi=vi=hi=null,bi=!1,t)throw Error(o(300));return e}function Ti(){var e=0!==_i;return _i=0,e}function xi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===yi?hi.memoizedState=yi=e:yi=yi.next=e,yi}function Fi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===yi?hi.memoizedState:yi.next;if(null!==t)yi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===yi?hi.memoizedState=yi=e:yi=yi.next=e}return yi}function Pi(e,t){return"function"===typeof t?t(e):t}function Ai(e){var t=Fi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var p={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=p,s=r):u=u.next=p,hi.lanes|=d,zl|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,zl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ei(e){var t=Fi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ni(){}function Ri(e,t){var n=hi,r=Fi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Hi(Ii.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==yi&&1&yi.memoizedState.tag){if(n.flags|=2048,Zi(9,Oi.bind(null,n,r,a,t),void 0,null),null===Al)throw Error(o(349));0!==(30&mi)||Mi(n,t,a)}return a}function Mi(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Oi(e,t,n,r){t.value=n,t.getSnapshot=r,zi(t)&&Di(e)}function Ii(e,t,n){return n((function(){zi(t)&&Di(e)}))}function zi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Di(e){var t=Eo(e,1);null!==t&&nu(t,e,1,-1)}function Li(e){var t=xi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Pi,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return Fi().memoizedState}function Bi(e,t,n,r){var a=xi();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Vi(e,t,n,r){var a=Fi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&ki(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Ui(e,t){return Bi(8390656,8,e,t)}function Hi(e,t){return Vi(2048,8,e,t)}function Wi(e,t){return Vi(4,2,e,t)}function Ji(e,t){return Vi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Gi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Vi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=Fi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=Fi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,zl|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=fi.transition;fi.transition={};try{e(!1),t()}finally{gt=n,fi.transition=r}}function es(){return Fi().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Ao(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Po(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Ao(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=bi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}var is={readContext:xo,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:xo,useCallback:function(e,t){return xi().memoizedState=[e,void 0===t?null:t],e},useContext:xo,useEffect:Ui,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=xi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=xi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},xi().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return xi().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Xi.bind(null,e[1]),xi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=xi();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Al)throw Error(o(349));0!==(30&mi)||Mi(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ui(Ii.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Oi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=xi(),t=Al.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Hi,useImperativeHandle:Gi,useInsertionEffect:Wi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ai,useRef:ji,useState:function(){return Ai(Pi)},useDebugValue:qi,useDeferredValue:function(e){return Yi(Fi(),vi.memoizedState,e)},useTransition:function(){return[Ai(Pi)[0],Fi().memoizedState]},useMutableSource:Ni,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1},us={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Hi,useImperativeHandle:Gi,useInsertionEffect:Wi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ei,useRef:ji,useState:function(){return Ei(Pi)},useDebugValue:qi,useDeferredValue:function(e){var t=Fi();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ei(Pi)[0],Fi().memoizedState]},useMutableSource:Ni,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function ps(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var fs="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Oo(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Hl||(Hl=!0,Wl=r),ps(0,t)},n}function hs(e,t,n){(n=Oo(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){ps(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){ps(0,t),"function"!==typeof r&&(null===Jl?Jl=new Set([this]):Jl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new fs;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Tu.bind(null,e,t,n),t.then(e,e))}function ys(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function bs(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Oo(-1,1)).tag=2,Io(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return To(t,a),r=Ci(e,t,n,r,o,a),n=Ti(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Hs(e,t,a))}function ks(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ru(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Ou(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Cs(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Hs(e,t,a)}return t.flags|=1,(e=Mu(o,r)).ref=t.ref,e.return=t,t.child=e}function Cs(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Hs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return Fs(e,t,n,r,a)}function Ts(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},xa(Ml,Rl),Rl|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,xa(Ml,Rl),Rl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,xa(Ml,Rl),Rl|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,xa(Ml,Rl),Rl|=r;return ws(e,t,a,n),t.child}function xs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function Fs(e,t,n,r,a){var o=Ra(n)?Ea:Pa.current;return o=Na(t,o),To(t,a),n=Ci(e,t,n,r,o,a),r=Ti(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Hs(e,t,a))}function Ps(e,t,n,r,a){if(Ra(n)){var o=!0;za(t)}else o=!1;if(To(t,a),null===t.stateNode)Us(e,t),Ho(t,n,r),Jo(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=xo(u):u=Na(t,u=Ra(n)?Ea:Pa.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Wo(t,i,r,u),No=!1;var p=t.memoizedState;i.state=p,Lo(t,r,i,a),l=t.memoizedState,s!==r||p!==l||Aa.current||No?("function"===typeof c&&(Bo(t,n,c,r),l=t.memoizedState),(s=No||Uo(t,n,s,r,p,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Mo(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:yo(t.type,s),i.props=u,d=t.pendingProps,p=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=xo(l):l=Na(t,l=Ra(n)?Ea:Pa.current);var f=n.getDerivedStateFromProps;(c="function"===typeof f||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||p!==l)&&Wo(t,i,r,l),No=!1,p=t.memoizedState,i.state=p,Lo(t,r,i,a);var m=t.memoizedState;s!==d||p!==m||Aa.current||No?("function"===typeof f&&(Bo(t,n,f,r),m=t.memoizedState),(u=No||Uo(t,n,u,r,p,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),r=!1)}return As(e,t,n,r,o,a)}function As(e,t,n,r,a,o){xs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&Da(t,n,!1),Hs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&Da(t,n,!0),t.child}function Es(e){var t=e.stateNode;t.pendingContext?Oa(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Oa(0,t.context,!1),ai(e,t.containerInfo)}function Ns(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Rs,Ms,Os,Is={dehydrated:null,treeContext:null,retryLane:0};function zs(e){return{baseLanes:e,cachePool:null,transitions:null}}function Ds(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),xa(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=zu(l,a,0,null),e=Iu(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=zs(n),t.memoizedState=Is,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=zu({mode:"visible",children:r.children},a,0,null),(i=Iu(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=zs(s),t.memoizedState=Is,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Al)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Eo(e,a),nu(r,e,a,-1))}return hu(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=Fu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Mu(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Mu(r,s):(s=Iu(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?zs(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Is,a}return e=(s=e.child).sibling,a=Mu(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=zu({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),Co(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Vs(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(xa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Us(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Hs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),zl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Mu(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Mu(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Ws(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Js(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Js(t),null;case 1:case 17:return Ra(t.type)&&Ma(),Js(t),null;case 3:return r=t.stateNode,oi(),Ta(Aa),Ta(Pa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(po(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),Js(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ms(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Js(t),null}if(e=ri(ei.current),po(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[pa]=t,r[fa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Ir.length;a++)Zr(Ir[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in be(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":J(r),X(r,i,!0);break;case"textarea":J(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[pa]=t,e[fa]=r,Rs(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Ir.length;a++)Zr(Ir[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=D({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in be(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&pe(e,c):"number"===typeof c&&pe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&Zr("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":J(e),X(e,r,!1);break;case"textarea":J(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+H(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Js(t),null;case 6:if(e&&null!=t.stateNode)Os(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),po(t)){if(r=t.stateNode,n=t.memoizedProps,r[pa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[pa]=t,t.stateNode=r}return Js(t),null;case 13:if(Ta(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))fo(),mo(),t.flags|=98560,i=!1;else if(i=po(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[pa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Js(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ol&&(Ol=3):hu())),null!==t.updateQueue&&(t.flags|=4),Js(t),null);case 4:return oi(),null===e&&Vr(t.stateNode.containerInfo),Js(t),null;case 10:return ko(t.type._context),Js(t),null;case 19:if(Ta(li),null===(i=t.memoizedState))return Js(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Ws(i,!1);else{if(0!==Ol||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Ws(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return xa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Vl&&(t.flags|=128,r=!0,Ws(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Ws(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Js(t),null}else 2*Qe()-i.renderingStartTime>Vl&&1073741824!==n&&(t.flags|=128,r=!0,Ws(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,xa(li,r?1&n|2:1&n),t):(Js(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Rl)&&(Js(t),6&t.subtreeFlags&&(t.flags|=8192)):Js(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Gs(e,t){switch(to(t),t.tag){case 1:return Ra(t.type)&&Ma(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Ta(Aa),Ta(Pa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Ta(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Ta(li),null;case 4:return oi(),null;case 10:return ko(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Rs=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ms=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=D({},a,{value:void 0}),r=D({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(c in be(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&Zr("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Os=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Cu(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Cu(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[pa],delete t[fa],delete t[ha],delete t[va],delete t[ya])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function pl(e,t,n){for(n=n.child;null!==n;)fl(e,t,n),n=n.sibling}function fl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=cl,a=dl;cl=null,pl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Vt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,pl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}pl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Cu(n,t,s)}pl(e,t,n);break;case 21:pl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,pl(e,t,n),Ks=r):pl(e,t,n);break;default:pl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Pu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));fl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){Cu(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),yl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Cu(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Cu(e,e.return,v)}}break;case 1:hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{pe(a,"")}catch(v){Cu(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],p=u[s+1];"style"===d?ve(a,p):"dangerouslySetInnerHTML"===d?de(a,p):"children"===d?pe(a,p):g(a,d,p,c)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var f=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):f!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[fa]=i}catch(v){Cu(e,e.return,v)}}break;case 6:if(hl(t,e),yl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Cu(e,e.return,v)}}break;case 3:if(hl(t,e),yl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Vt(t.containerInfo)}catch(v){Cu(e,e.return,v)}break;case 4:default:hl(t,e),yl(e);break;case 13:hl(t,e),yl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),yl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(p=Ys=d;null!==Ys;){switch(m=(f=Ys).child,f.tag){case 0:case 11:case 14:case 15:nl(4,f,f.return);break;case 1:Xs(f,f.return);var h=f.stateNode;if("function"===typeof h.componentWillUnmount){r=f,n=f.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Cu(r,n,v)}}break;case 5:Xs(f,f.return);break;case 22:if(null!==f.memoizedState){wl(p);continue}}null!==m?(m.return=f,Ys=m):wl(p)}d=d.sibling}e:for(d=null,p=e;;){if(5===p.tag){if(null===d){d=p;try{a=p.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=p.stateNode,s=void 0!==(u=p.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){Cu(e,e.return,v)}}}else if(6===p.tag){if(null===d)try{p.stateNode.nodeValue=c?"":p.memoizedProps}catch(v){Cu(e,e.return,v)}}else if((22!==p.tag&&23!==p.tag||null===p.memoizedState||p===e)&&null!==p.child){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;null===p.sibling;){if(null===p.return||p.return===e)break e;d===p&&(d=null),p=p.return}d===p&&(d=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:hl(t,e),yl(e),4&r&&ml(e);case 21:}}function yl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(pe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Cu(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function bl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Ys=l):Sl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:yo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var p=d.dehydrated;null!==p&&Vt(p)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(f){Cu(t,t.return,f)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Sl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Cu(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Cu(t,a,l)}}var o=t.return;try{al(t)}catch(l){Cu(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Cu(t,i,l)}}}catch(l){Cu(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var kl,Cl=Math.ceil,Tl=_.ReactCurrentDispatcher,xl=_.ReactCurrentOwner,Fl=_.ReactCurrentBatchConfig,Pl=0,Al=null,El=null,Nl=0,Rl=0,Ml=Ca(0),Ol=0,Il=null,zl=0,Dl=0,Ll=0,Zl=null,jl=null,Bl=0,Vl=1/0,Ul=null,Hl=!1,Wl=null,Jl=null,$l=!1,Gl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function eu(){return 0!==(6&Pl)?Qe():-1!==Yl?Yl:Yl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&Pl)&&0!==Nl?Nl&-Nl:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));yt(e,n,r),0!==(2&Pl)&&e===Al||(e===Al&&(0===(2&Pl)&&(Dl|=n),4===Ol&&su(e,Nl)),ru(e,r),1===n&&0===Pl&&0===(1&t.mode)&&(Vl=Qe()+500,Za&&Va()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=ft(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=pt(e,e===Al?Nl:0);if(0===r)null!==n&&Ge(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Ge(n),1===t)0===e.tag?function(e){Za=!0,Ba(e)}(lu.bind(null,e)):Ba(lu.bind(null,e)),ia((function(){0===(6&Pl)&&Va()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Au(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Yl=-1,Xl=0,0!==(6&Pl))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=pt(e,e===Al?Nl:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=Pl;Pl|=2;var i=mu();for(Al===e&&Nl===t||(Ul=null,Vl=Qe()+500,pu(e,t));;)try{bu();break}catch(l){fu(e,l)}So(),Tl.current=i,Pl=a,null!==El?t=0:(Al=null,Nl=0,t=Ol)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Il,pu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Il,pu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,jl,Ul);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=Bl+500-Qe())){if(0!==pt(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,jl,Ul),t);break}wu(e,jl,Ul);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Cl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,jl,Ul),r);break}wu(e,jl,Ul);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(pu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=jl,jl=n,null!==t&&iu(t)),e}function iu(e){null===jl?jl=e:jl.push.apply(jl,e)}function su(e,t){for(t&=~Ll,t&=~Dl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&Pl))throw Error(o(327));Su();var t=pt(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Il,pu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,jl,Ul),ru(e,Qe()),null}function uu(e,t){var n=Pl;Pl|=1;try{return e(t)}finally{0===(Pl=n)&&(Vl=Qe()+500,Za&&Va())}}function cu(e){null!==Gl&&0===Gl.tag&&0===(6&Pl)&&Su();var t=Pl;Pl|=1;var n=Fl.transition,r=gt;try{if(Fl.transition=null,gt=1,e)return e()}finally{gt=r,Fl.transition=n,0===(6&(Pl=t))&&Va()}}function du(){Rl=Ml.current,Ta(Ml)}function pu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==El)for(n=El.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Ma();break;case 3:oi(),Ta(Aa),Ta(Pa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Ta(li);break;case 10:ko(r.type._context);break;case 22:case 23:du()}n=n.return}if(Al=e,El=e=Mu(e.current,null),Nl=Rl=t,Ol=0,Il=null,Ll=Dl=zl=0,jl=Zl=null,null!==Fo){for(t=0;t<Fo.length;t++)if(null!==(r=(n=Fo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}Fo=null}return e}function fu(e,t){for(;;){var n=El;try{if(So(),pi.current=is,bi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}bi=!1}if(mi=0,yi=vi=hi=null,gi=!1,_i=0,xl.current=null,null===n||null===n.return){Ol=1,Il=t,El=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=Nl,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,p=d.tag;if(0===(1&d.mode)&&(0===p||11===p||15===p)){var f=d.alternate;f?(d.updateQueue=f.updateQueue,d.memoizedState=f.memoizedState,d.lanes=f.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=ys(s);if(null!==m){m.flags&=-257,bs(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var y=ys(s);if(null!==y){0===(65536&y.flags)&&(y.flags|=256),bs(y,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Ol&&(Ol=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Do(i,ms(0,u,t));break e;case 1:l=u;var b=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof b.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Jl||!Jl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Do(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,El===n&&null!==n&&(El=n=n.return);continue}break}}function mu(){var e=Tl.current;return Tl.current=is,null===e?is:e}function hu(){0!==Ol&&3!==Ol&&2!==Ol||(Ol=4),null===Al||0===(268435455&zl)&&0===(268435455&Dl)||su(Al,Nl)}function vu(e,t){var n=Pl;Pl|=2;var r=mu();for(Al===e&&Nl===t||(Ul=null,pu(e,t));;)try{yu();break}catch(a){fu(e,a)}if(So(),Pl=n,Tl.current=r,null!==El)throw Error(o(261));return Al=null,Nl=0,Ol}function yu(){for(;null!==El;)gu(El)}function bu(){for(;null!==El&&!qe();)gu(El)}function gu(e){var t=kl(e.alternate,e,Rl);e.memoizedProps=e.pendingProps,null===t?_u(e):El=t,xl.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Rl)))return void(El=n)}else{if(null!==(n=Gs(n,t)))return n.flags&=32767,void(El=n);if(null===e)return Ol=6,void(El=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(El=t);El=t=e}while(null!==t);0===Ol&&(Ol=5)}function wu(e,t,n){var r=gt,a=Fl.transition;try{Fl.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Gl);if(0!==(6&Pl))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Al&&(El=Al=null,Nl=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Au(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=Fl.transition,Fl.transition=null;var s=gt;gt=1;var l=Pl;Pl|=4,xl.current=null,function(e,t){if(ea=Ht,fr(e=pr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,p=e,f=null;t:for(;;){for(var m;p!==n||0!==a&&3!==p.nodeType||(l=s+a),p!==i||0!==r&&3!==p.nodeType||(u=s+r),3===p.nodeType&&(s+=p.nodeValue.length),null!==(m=p.firstChild);)f=p,p=m;for(;;){if(p===e)break t;if(f===n&&++c===a&&(l=s),f===i&&++d===r&&(u=s),null!==(m=p.nextSibling))break;f=(p=f).parentNode}p=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Ht=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,y=h.memoizedState,b=t.stateNode,g=b.getSnapshotBeforeUpdate(t.elementType===t.type?v:yo(t.type,v),y);b.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Cu(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Ht=!!ea,ta=ea=null,e.current=n,bl(n,e,a),Ke(),Pl=l,gt=s,Fl.transition=i}else e.current=n;if($l&&($l=!1,Gl=e,ql=a),0===(i=e.pendingLanes)&&(Jl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Hl)throw Hl=!1,e=Wl,Wl=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Va()}(e,t,n,r)}finally{Fl.transition=a,gt=r}return null}function Su(){if(null!==Gl){var e=_t(ql),t=Fl.transition,n=gt;try{if(Fl.transition=null,gt=16>e?16:e,null===Gl)var r=!1;else{if(e=Gl,Gl=null,ql=0,0!==(6&Pl))throw Error(o(331));var a=Pl;for(Pl|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Ys=c;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var p=d.child;if(null!==p)p.return=d,Ys=p;else for(;null!==Ys;){var f=(d=Ys).sibling,m=d.return;if(ol(d),d===c){Ys=null;break}if(null!==f){f.return=m,Ys=f;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var y=v.sibling;v.sibling=null,v=y}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var b=i.sibling;if(null!==b){b.return=i.return,Ys=b;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Cu(l,l.return,S)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(Pl=a,Va(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,Fl.transition=t}}return!1}function ku(e,t,n){e=Io(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(yt(e,1,t),ru(e,t))}function Cu(e,t,n){if(3===e.tag)ku(e,e,n);else for(;null!==t;){if(3===t.tag){ku(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Jl||!Jl.has(r))){t=Io(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(yt(t,1,e),ru(t,e));break}}t=t.return}}function Tu(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Al===e&&(Nl&n)===n&&(4===Ol||3===Ol&&(130023424&Nl)===Nl&&500>Qe()-Bl?pu(e,0):Ll|=n),ru(e,t)}function xu(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=Eo(e,t))&&(yt(e,t,n),ru(e,n))}function Fu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),xu(e,n)}function Pu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),xu(e,n)}function Au(e,t){return $e(e,t)}function Eu(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Nu(e,t,n,r){return new Eu(e,t,n,r)}function Ru(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Mu(e,t){var n=e.alternate;return null===n?((n=Nu(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Ou(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ru(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case k:return Iu(n.children,a,i,t);case C:s=8,a|=8;break;case T:return(e=Nu(12,n,t,2|a)).elementType=T,e.lanes=i,e;case A:return(e=Nu(13,n,t,a)).elementType=A,e.lanes=i,e;case E:return(e=Nu(19,n,t,a)).elementType=E,e.lanes=i,e;case M:return zu(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case x:s=10;break e;case F:s=9;break e;case P:s=11;break e;case N:s=14;break e;case R:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Nu(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Iu(e,t,n,r){return(e=Nu(7,e,r,t)).lanes=n,e}function zu(e,t,n,r){return(e=Nu(22,e,r,t)).elementType=M,e.lanes=n,e.stateNode={isHidden:!1},e}function Du(e,t,n){return(e=Nu(6,e,null,t)).lanes=n,e}function Lu(e,t,n){return(t=Nu(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zu(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function ju(e,t,n,r,a,o,i,s,l){return e=new Zu(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Nu(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Ro(o),e}function Bu(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Vu(e){if(!e)return Fa;e:{if(Ve(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Ra(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Ra(n))return Ia(e,n,t)}return t}function Uu(e,t,n,r,a,o,i,s,l){return(e=ju(n,r,!0,e,0,o,0,s,l)).context=Vu(null),n=e.current,(o=Oo(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Io(n,o,a),e.current.lanes=a,yt(e,a,r),ru(e,r),e}function Hu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Vu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Oo(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Io(a,t,i))&&(nu(e,a,i,o),zo(e,a,i)),i}function Wu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Ju(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $u(e,t){Ju(e,t),(e=e.alternate)&&Ju(e,t)}kl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Aa.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Es(t),mo();break;case 5:ii(t);break;case 1:Ra(t.type)&&za(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;xa(bo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(xa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Ds(e,t,n):(xa(li,1&li.current),null!==(e=Hs(e,t,n))?e.sibling:null);xa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Vs(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),xa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Ts(e,t,n)}return Hs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ja,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Us(e,t),e=t.pendingProps;var a=Na(t,Pa.current);To(t,n),a=Ci(null,t,r,e,a,n);var i=Ti();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Ra(r)?(i=!0,za(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Ro(t),a.updater=Vo,t.stateNode=a,a._reactInternals=t,Jo(t,r,e,n),t=As(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Us(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ru(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===P)return 11;if(e===N)return 14}return 2}(r),e=yo(r,e),a){case 0:t=Fs(null,t,r,e,n);break e;case 1:t=Ps(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=ks(null,t,r,yo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,Fs(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Ps(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 3:e:{if(Es(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Mo(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Ns(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=Ns(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Hs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),xs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return Ds(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,xa(bo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Aa.current){t=Hs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Oo(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),Co(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),Co(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,To(t,n),r=r(a=xo(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=yo(r=t.type,t.pendingProps),ks(e,t,r,a=yo(r.type,a),n);case 15:return Cs(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:yo(r,a),Us(e,t),t.tag=1,Ra(r)?(e=!0,za(t)):e=!1,To(t,n),Ho(t,r,a),Jo(t,r,a,n),As(null,t,r,!0,e,n);case 19:return Vs(e,t,n);case 22:return Ts(e,t,n)}throw Error(o(156,t.tag))};var Gu="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Wu(i);s.call(e)}}Hu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Wu(i);o.call(e)}}var i=Uu(t,r,e,0,null,!1,0,"",Xu);return e._reactRootContainer=i,e[ma]=i.current,Vr(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Wu(l);s.call(e)}}var l=ju(e,0,!1,null,0,!1,0,"",Xu);return e._reactRootContainer=l,e[ma]=l.current,Vr(8===e.nodeType?e.parentNode:e),cu((function(){Hu(t,l,n,r)})),l}(n,t,e,a,r);return Wu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Hu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Hu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=Ct();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Mt.length&&0!==t&&t<Mt[n].priority;n++);Mt.splice(n,0,e),0===n&&Dt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(bt(t,1|n),ru(t,Qe()),0===(6&Pl)&&(Vl=Qe()+500,Va()))}break;case 13:cu((function(){var t=Eo(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),$u(e,1)}},St=function(e){if(13===e.tag){var t=Eo(e,134217728);if(null!==t)nu(t,e,134217728,eu());$u(e,134217728)}},kt=function(e){if(13===e.tag){var t=tu(e),n=Eo(e,t);if(null!==n)nu(n,e,t,eu());$u(e,t)}},Ct=function(){return gt},Tt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Pe=uu,Ae=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,xe,Fe,uu]},nc={findFiberByHostInstance:ba,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=We(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return Bu(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Gu;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=ju(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Vr(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=We(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Gu;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Uu(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Vr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),p=Symbol.for("react.lazy"),f=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function y(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function b(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}y.prototype.isReactComponent={},y.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},y.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},b.prototype=y.prototype;var _=g.prototype=new b;_.constructor=g,h(_,y.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,k={current:null},C={key:!0,ref:!0,__self:!0,__source:!0};function T(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!C.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:k.current}}function x(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var F=/\/+/g;function P(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function A(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+P(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(F,"$&/")+"/"),A(i,t,a,"",(function(e){return e}))):null!=i&&(x(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(F,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+P(s=e[u],u);l+=A(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=f&&e[f]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=A(s=s.value,t,a,c=o+P(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function E(e,t,n){if(null==e)return e;var r=[],a=0;return A(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function N(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var R={current:null},M={transition:null},O={ReactCurrentDispatcher:R,ReactCurrentBatchConfig:M,ReactCurrentOwner:k};t.Children={map:E,forEach:function(e,t,n){E(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return E(e,(function(){t++})),t},toArray:function(e){return E(e,(function(e){return e}))||[]},only:function(e){if(!x(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=y,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=O,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=k.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!C.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=T,t.createFactory=function(e){var t=T.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=x,t.lazy=function(e){return{$$typeof:p,_payload:{_status:-1,_result:e},_init:N}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=M.transition;M.transition={};try{e()}finally{M.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return R.current.useCallback(e,t)},t.useContext=function(e){return R.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return R.current.useDeferredValue(e)},t.useEffect=function(e,t){return R.current.useEffect(e,t)},t.useId=function(){return R.current.useId()},t.useImperativeHandle=function(e,t,n){return R.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return R.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return R.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return R.current.useMemo(e,t)},t.useReducer=function(e,t,n){return R.current.useReducer(e,t,n)},t.useRef=function(e){return R.current.useRef(e)},t.useState=function(e){return R.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return R.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return R.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,p=null,f=3,m=!1,h=!1,v=!1,y="function"===typeof setTimeout?setTimeout:null,b="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,M(S);else{var t=r(c);null!==t&&O(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,b(x),x=-1),m=!0;var o=f;try{for(_(n),p=r(u);null!==p&&(!(p.expirationTime>n)||e&&!A());){var i=p.callback;if("function"===typeof i){p.callback=null,f=p.priorityLevel;var s=i(p.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?p.callback=s:p===r(u)&&a(u),_(n)}else a(u);p=r(u)}if(null!==p)var l=!0;else{var d=r(c);null!==d&&O(w,d.startTime-n),l=!1}return l}finally{p=null,f=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var k,C=!1,T=null,x=-1,F=5,P=-1;function A(){return!(t.unstable_now()-P<F)}function E(){if(null!==T){var e=t.unstable_now();P=e;var n=!0;try{n=T(!0,e)}finally{n?k():(C=!1,T=null)}}else C=!1}if("function"===typeof g)k=function(){g(E)};else if("undefined"!==typeof MessageChannel){var N=new MessageChannel,R=N.port2;N.port1.onmessage=E,k=function(){R.postMessage(null)}}else k=function(){y(E,0)};function M(e){T=e,C||(C=!0,k())}function O(e,n){x=y((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,M(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):F=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return f},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(f){case 1:case 2:case 3:var t=3;break;default:t=f}var n=f;f=t;try{return e()}finally{f=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=f;f=e;try{return t()}finally{f=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(b(x),x=-1):v=!0,O(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,M(S))),e},t.unstable_shouldYield=A,t.unstable_wrapCallback=function(e){var t=f;return function(){var n=f;f=t;try{return e.apply(this,arguments)}finally{f=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var p=n(184);function f(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,p.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,p.jsx)(f,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},y=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var b=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},y(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),k=n(7312),C=n(1217),T=n(4419),x=n(8691),F=(0,n(4046).ZP)(),P=n(5080),A=["className","component","disableGutters","fixed","maxWidth","classes"],E=(0,P.Z)(),N=F("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,k.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),R=function(e){return(0,x.Z)({props:e,name:"MuiContainer",defaultTheme:E})},M=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,k.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,T.Z)(i,(function(e){return(0,C.Z)(t,e)}),n)};var O=n(9853),I=n(277),z=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?N:n,o=t.useThemeProps,i=void 0===o?R:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,f=n.fixed,m=void 0!==f&&f,h=n.maxWidth,v=void 0===h?"lg":h,y=(0,w.Z)(n,A),b=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=M(b,l);return(0,p.jsx)(u,(0,r.Z)({as:s,ownerState:b,className:(0,S.Z)(g.root,a),ref:t},y))}));return c}({createStyledComponent:(0,I.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,O.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),D=z,L=n(2421),Z=n(104),j=n(2982),B=n(2466),V=n(114),U=["sx"];function H(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){V.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,U)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var W=n(886),J=["className","component"];var $=n(5902),G=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,u=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,W.Z)(n),s=H(e),l=s.className,c=s.component,d=void 0===c?"div":c,f=(0,w.Z)(s,J);return(0,p.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},f))}));return c}({defaultTheme:(0,G.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Q=JSON.parse('{"e":14,"C":[{"nctid":"NCT03654729","version_a":11,"version_b":12,"version_a_date":"2020-10-09","version_b_date":"2021-08-31","pom_a":[{"label":"1.","content":"Moderate or severe chronic chemotherapy induced peripheral neuropathy (CIPN)[ Time Frame: 9 months ]Proportion of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e., FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy)."}],"pom_b":[{"label":"1.","content":"Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)[ Time Frame: 9 months ]Proportion of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e., FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy)."}],"start_date":"November 7, 2018","primary_completion_date":"August 31, 2020","completion_date":"August 31, 2020","first_posted":"August 31, 2018","results_first_posted":"December 17, 2021","last_update_posted":"December 17, 2021"},{"nctid":"NCT03654729","version_a":12,"version_b":13,"version_a_date":"2021-08-31","version_b_date":"2021-10-08","pom_a":[{"label":"1.","content":"Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)[ Time Frame: 9 months ]Proportion of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the FACT/GOG-NTX-13 (i.e., FACT/GOG-NTX-4), targeting numbness, tingling or discomfort in hands and/or feet, 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy)."}],"pom_b":[{"label":"1.","content":"Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)[ Time Frame: 9 months ]Percentage of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity-13-item subscale (FACT/GOG-NTX-13; i.e., FACT/GOG-NTX-4) 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy). The FACT/GOG-13 questionnaire includes 13 items that measure the severity and impact of symptoms of neurotoxicity over the past 7 days. Patients rate each item as 0 (\\"not at all\\"), 1 (\\" a little bit\\"), 2 (\\"somewhat\\"), 3 (\\"quite a bit\\") or 4 (\\"very much\\"). These 13 items are summed to create a total score, ranging from 0 to 52, with a higher score representing a worse outcome. The FACT/GOG-NTX-4 is a 4 item subscale targeting numbness, tingling or discomfort in hands and/or feet."}],"start_date":"November 7, 2018","primary_completion_date":"August 31, 2020","completion_date":"August 31, 2020","first_posted":"August 31, 2018","results_first_posted":"December 17, 2021","last_update_posted":"December 17, 2021"},{"nctid":"NCT01522443","version_a":34,"version_b":35,"version_a_date":"2015-02-19","version_b_date":"2018-04-23","pom_a":[{"label":"1.","content":"Confirmed pain response at Week 12 durable since Week 6[ Time Frame: Week 6 and 12 ]Subjects will self-report information on pain and health-related quality of life via an interactive voice recognition system"}],"pom_b":[{"label":"1.","content":"Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported[ Time Frame: Pain response was measured at Week 6 and Week 12 by self-reports of subjects ]The pre-specified primary analysis of Pain Response at Week 6 confirmed at Week 12 was defined as \u2265 30% from baseline in the average daily worst pain intensity score during a 7-day reporting period, with neither a concomitant increase in average daily use of any opioid narcotic type, nor addition of any new opioid narcotic type, relative to baseline. Pain Progression at a given time point is defined as \u2265 30% increase compared with baseline in the average daily worst pain intensity score during a 7-day reporting period or either an increase in the average daily use of any type of opioid narcotic or addition of a new opioid narcotic type compared with baseline."}],"start_date":"March 2012","primary_completion_date":"October 2014","completion_date":"January 13, 2015","first_posted":"January 31, 2012","results_first_posted":"May 23, 2018","last_update_posted":"May 23, 2018"},{"nctid":"NCT03556358","version_a":20,"version_b":21,"version_a_date":"2021-04-13","version_b_date":"2021-10-28","pom_a":[{"label":"1.","content":"Pathologic complete response (pCR)[ Time Frame: 3-7 weeks following last dose of study treatment ]The absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0)"}],"pom_b":[{"label":"1.","content":"Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)[ Time Frame: 3-7 weeks following last dose of study treatment ]Pathologic complete response was determined by central review and defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0)."}],"start_date":"June 28, 2018","primary_completion_date":"November 27, 2020","completion_date":"February 4, 2021","first_posted":"June 14, 2018","results_first_posted":"January 14, 2022","last_update_posted":"January 14, 2022"},{"nctid":"NCT02694536","version_a":1,"version_b":2,"version_a_date":"2016-02-24","version_b_date":"2016-11-11","pom_a":[{"label":"1.","content":"Percentage of Participants with Adverse Events (AEs)[ Time Frame: Continuously during treatment (up to approximately 12 months) ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Adverse Events (AEs)[ Time Frame: Up to approximately 40 months (assessed continuously during treatment) ]An AE was defined as any untoward medical occurrence and which did not necessarily have a causal relationship with treatment. The percentage of participants who experienced at least 1 AE was reported."}],"start_date":"August 1, 2006","primary_completion_date":"November 19, 2009","completion_date":"November 19, 2009","first_posted":"February 29, 2016","results_first_posted":"January 10, 2017","last_update_posted":"March 24, 2017"},{"nctid":"NCT02163694","version_a":25,"version_b":26,"version_a_date":"2019-09-20","version_b_date":"2020-01-10","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Measured up to 5 years after the last subject has enrolled in the study. ]Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Measured up to 3 years after the last subject has enrolled in the study. ]Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached"}],"start_date":"July 17, 2014","primary_completion_date":"April 5, 2019","completion_date":"August 5, 2022","first_posted":"June 16, 2014","results_first_posted":"April 4, 2022","last_update_posted":"June 14, 2022"},{"nctid":"NCT02163694","version_a":27,"version_b":28,"version_a_date":"2020-04-01","version_b_date":"2020-08-17","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Measured up to 3 years after the last subject has enrolled in the study. ]Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached"}],"pom_b":[{"label":"1.","content":"Progression free survival (PFS)[ Time Frame: Measured up to 3 years after the last subject has enrolled in the study. ]Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached"}],"start_date":"July 17, 2014","primary_completion_date":"April 5, 2019","completion_date":"August 5, 2022","first_posted":"June 16, 2014","results_first_posted":"April 4, 2022","last_update_posted":"June 14, 2022"},{"nctid":"NCT02163694","version_a":30,"version_b":31,"version_a_date":"2022-01-20","version_b_date":"2022-03-11","pom_a":[{"label":"1.","content":"Progression free survival (PFS)[ Time Frame: Measured up to 3 years after the last subject has enrolled in the study. ]Number of days from the date the subject is randomized to the date the subject experiences a confirmed event of disease progression or to the date of death if disease progression is not reached"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: From randomization until the primary analysis data cut-off date of 05 April 2019; the median duration of follow-up was 35.5 months ]Time to PFS is defined as the number of days from the date the participant was randomized to the date the participant experiences radiographic disease progression (as determined by the investigators), or to the date of death (all causes of mortality) if disease progression is not reached. All events of disease progression occurring on or before the Primary Analysis Cutoff date of 05 April 2019 were to be included, regardless of whether the event occurred while the participant was still taking study drug or had previously discontinued study drug. PFS was estimated for each treatment group using Kaplan-Meier methodology."}],"start_date":"July 17, 2014","primary_completion_date":"April 5, 2019","completion_date":"August 5, 2022","first_posted":"June 16, 2014","results_first_posted":"April 4, 2022","last_update_posted":"June 14, 2022"},{"nctid":"NCT04660344","version_a":26,"version_b":27,"version_a_date":"2022-07-25","version_b_date":"2022-08-19","pom_a":[{"label":"1.","content":"IRF-assessed DFS in Participants Who Are ctDNA Positive Within 20 Weeks of Cystectomy[ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]Independent Review Facility(IRF)-assessed disease-free survival (DFS) in participants who are ctDNA positive within 20 weeks of cystectomy (primary analysis population), defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following:Local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes)Urinary tract recurrence of UC (including all pathological stages and grades)Distant metastasis of UCDeath from any cause"}],"pom_b":[{"label":"1.","content":"Investigator-assessed DFS in Participants Who Are ctDNA Positive Within 24 Weeks of Cystectomy[ Time Frame: Randomization up to first occurrence of DFS event (up to approximately 73 months) ]Investigator-assessed disease-free survival (DFS) in participants who are ctDNA positive within 24 weeks of cystectomy (primary analysis population), defined as the time from randomization to the first occurrence of a DFS event, defined as any of the following:Local (pelvic) recurrence of urothelial carcinoma (UC) (including soft tissue and regional lymph nodes)Urinary tract recurrence of UC (including all pathological stages and grades)Distant metastasis of UCDeath from any cause"}],"start_date":"May 3, 2021","primary_completion_date":"May 11, 2024","completion_date":"November 22, 2027","first_posted":"December 9, 2020","last_update_posted":"September 16, 2022"},{"nctid":"NCT00003739","version_a":15,"version_b":16,"version_a_date":"2010-02-12","version_b_date":"2014-02-12","pom_a":[],"pom_b":[{"label":"1.","content":"Time to Resolution of Febrile NeutropeniaTime to Resolution of Febrile Neutropenia (Days of antibiotic treatment until the resolution of febrile neutropenia): The time to resolution of febrile neutropenia is defined as the number of days elapsed before the first day with both a temperature of less than 38.0oC and an ANC of equal to or greater than 500/\u03bcL."}],"start_date":"March 1999","primary_completion_date":"December 2002","completion_date":"September 2006","first_posted":"January 27, 2003","last_update_posted":"February 14, 2014"},{"nctid":"NCT00206440","version_a":4,"version_b":5,"version_a_date":"2007-06-14","version_b_date":"2007-12-07","pom_a":[{"label":"1.","content":"The purpose of this study is to determine whether esomeprazole significantly decreases the incidence, severity and duration of nausea/vomiting/retching in breast cancer patients who are receiving anthracycline-based chemotherapy."}],"pom_b":[{"label":"1.","content":"The purpose of this study is to determine whether esomeprazole significantly decreases the incidence, severity and duration of nausea/vomiting/retching in breast cancer patients who are receiving anthracycline-based chemotherapy.[ Time Frame: 10 years ]"}],"start_date":"August 2005","primary_completion_date":"February 2009","completion_date":"February 2012","first_posted":"September 21, 2005","results_first_posted":"March 7, 2012","last_update_posted":"December 6, 2018"},{"nctid":"NCT00206440","version_a":10,"version_b":11,"version_a_date":"2012-01-24","version_b_date":"2012-02-03","pom_a":[{"label":"1.","content":"The purpose of this study is to determine whether esomeprazole significantly decreases the incidence, severity and duration of nausea/vomiting/retching in breast cancer patients who are receiving anthracycline-based chemotherapy.[ Time Frame: 10 years ]"}],"pom_b":[{"label":"1.","content":"The Purpose of This Study is to Determine Whether Esomeprazole Significantly Decreases the Incidence, Severity and Duration of Nausea/Vomiting/Retching in Breast Cancer Patients Who Are Receiving Anthracycline-based Chemotherapy.[ Time Frame: 10 years ]Proportion of patients who exhibit no more than one emetic episode and who do not require rescue medication for nausea from 2-7 days following chemotherapy."}],"start_date":"August 2005","primary_completion_date":"February 2009","completion_date":"February 2012","first_posted":"September 21, 2005","results_first_posted":"March 7, 2012","last_update_posted":"December 6, 2018"},{"nctid":"NCT00206440","version_a":11,"version_b":12,"version_a_date":"2012-02-03","version_b_date":"2012-04-27","pom_a":[{"label":"1.","content":"The Purpose of This Study is to Determine Whether Esomeprazole Significantly Decreases the Incidence, Severity and Duration of Nausea/Vomiting/Retching in Breast Cancer Patients Who Are Receiving Anthracycline-based Chemotherapy.[ Time Frame: 10 years ]Proportion of patients who exhibit no more than one emetic episode and who do not require rescue medication for nausea from 2-7 days following chemotherapy."}],"pom_b":[{"label":"1.","content":"Number of Times a Subject Felt Sick to Her Stomach and Number of Times a Subject Required Rescue Medication[ Time Frame: 2-7 days following chemotheraphy ]Proportion of patients who exhibit no more than one emetic episode and who do not require rescue medication for nausea from 2-7 days following chemotherapy."}],"start_date":"August 2005","primary_completion_date":"February 2009","completion_date":"February 2012","first_posted":"September 21, 2005","results_first_posted":"March 7, 2012","last_update_posted":"December 6, 2018"},{"nctid":"NCT00206440","version_a":13,"version_b":14,"version_a_date":"2018-08-07","version_b_date":"2018-11-09","pom_a":[{"label":"1.","content":"Number of Times a Subject Felt Sick to Her Stomach and Number of Times a Subject Required Rescue Medication[ Time Frame: 2-7 days following chemotheraphy ]Proportion of patients who exhibit no more than one emetic episode and who do not require rescue medication for nausea from 2-7 days following chemotherapy."}],"pom_b":[{"label":"1.","content":"Number of Times a Subject Felt Sick to Her Stomach and Number of Times a Subject Required Rescue Medication[ Time Frame: 2-7 days following chemotheraphy ]Proportion of patients who exhibit no more than one emetic episode and who do not require rescue medication for nausea from 2-7 days following chemotherapy. Thus, we will look at esomeprazole when used to decrease the incidence,severity and duration of nausea/vomiting/retching in breast cancer patients who are receiving anthracycline-based chemotherapy."}],"start_date":"August 2005","primary_completion_date":"February 2009","completion_date":"February 2012","first_posted":"September 21, 2005","results_first_posted":"March 7, 2012","last_update_posted":"December 6, 2018"},{"nctid":"NCT04662255","version_a":7,"version_b":8,"version_a_date":"2021-11-11","version_b_date":"2022-02-11","pom_a":[{"label":"1.","content":"To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)[ Time Frame: Up to approximately 24 months ]Assessed per Lugano criteria"}],"pom_b":[{"label":"1.","content":"To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)[ Time Frame: Up to approximately 24 months ]Assessed per Lugano criteria"}],"start_date":"April 8, 2021","primary_completion_date":"April 2025","completion_date":"April 2025","first_posted":"December 10, 2020","last_update_posted":"August 30, 2022"},{"nctid":"NCT00687349","version_a":6,"version_b":7,"version_a_date":"2010-10-08","version_b_date":"2011-03-24","pom_a":[{"label":"1.","content":"Patient and family ratings on the \\"End-of-Life domain\\" of the Quality of Communication Questionaire (QOC)[ Time Frame: 4/1/2007-3/31/2012 ]"}],"pom_b":[],"start_date":"April 2007","primary_completion_date":"February 2013","completion_date":"March 2013","first_posted":"May 30, 2008","last_update_posted":"September 16, 2014"},{"nctid":"NCT00687349","version_a":7,"version_b":8,"version_a_date":"2011-03-24","version_b_date":"2012-04-26","pom_a":[],"pom_b":[{"label":"1.","content":"Patient and family ratings on the \\"End-of-Life domain\\" of the Quality of Communication Questionaire (QOC)[ Time Frame: 4/1/2007-3/31/2012 ]"}],"start_date":"April 2007","primary_completion_date":"February 2013","completion_date":"March 2013","first_posted":"May 30, 2008","last_update_posted":"September 16, 2014"},{"nctid":"NCT00566852","version_a":51,"version_b":52,"version_a_date":"2008-10-29","version_b_date":"2008-10-31","pom_a":[{"label":"1.","content":"Cognitive function, specifically memory, from baseline to 24 weeks from the start of drug treatment as measured by the Hopkins Verbal Learning Test for delayed recall (HVLT-delayed recall)"}],"pom_b":[{"label":"1.","content":"Cognitive function, specifically memory, 24 weeks from the start of drug treatment as measured by the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-delayed recall)"}],"start_date":"March 2008","primary_completion_date":"April 2011","completion_date":"December 2016","first_posted":"December 4, 2007","results_first_posted":"July 21, 2017","last_update_posted":"August 21, 2017"},{"nctid":"NCT00566852","version_a":268,"version_b":269,"version_a_date":"2010-07-23","version_b_date":"2013-11-21","pom_a":[{"label":"1.","content":"Cognitive function, specifically memory, 24 weeks from the start of drug treatment as measured by the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-delayed recall)"}],"pom_b":[{"label":"1.","content":"Cognitive function, specifically memory, 24 weeks from the start of drug treatment as measured by the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-delayed recall)[ Time Frame: Baseline to 24 weeks from the start of drug treatment ]"}],"start_date":"March 2008","primary_completion_date":"April 2011","completion_date":"December 2016","first_posted":"December 4, 2007","results_first_posted":"July 21, 2017","last_update_posted":"August 21, 2017"},{"nctid":"NCT00566852","version_a":271,"version_b":272,"version_a_date":"2015-03-26","version_b_date":"2017-06-22","pom_a":[{"label":"1.","content":"Cognitive function, specifically memory, 24 weeks from the start of drug treatment as measured by the Hopkins Verbal Learning Test-Revised for delayed recall (HVLT-R-delayed recall)[ Time Frame: Baseline to 24 weeks from the start of drug treatment ]"}],"pom_b":[{"label":"1.","content":"Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall) at 24 Weeks[ Time Frame: Baseline and 24 weeks from the start of drug treatment ]The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. Standardized scores are used by calculating an average standardized z score for each part of the HVLT-R. Change is calculated by subtracting baseline value from 24-week value. Imputation methods were used to determine values for all alive patients missing the 24 week assessment. This tool is being used to measure cognitive function, specifically memory."}],"start_date":"March 2008","primary_completion_date":"April 2011","completion_date":"December 2016","first_posted":"December 4, 2007","results_first_posted":"July 21, 2017","last_update_posted":"August 21, 2017"},{"nctid":"NCT01876784","version_a":2,"version_b":3,"version_a_date":"2013-06-18","version_b_date":"2013-07-31","pom_a":[{"label":"1.","content":"Determination of the efficacy (as assessed by progression-free survival) of vandetanib when compared to placebo in the patient population[ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow-up). ]Once 155 progression events have occurred. RECIST measurements taken every 12 weeks from randomization. Time point(s) at which outcome measure is assessed."}],"pom_b":[{"label":"1.","content":"Determination of the efficacy (as assessed by progression-free survival) of vandetanib when compared to placebo in the patient population[ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow-up). RECIST measurements taken every 12 weeks from randomization ]Once 155 progression events have occurred."}],"start_date":"September 17, 2013","primary_completion_date":"August 30, 2015","completion_date":"December 31, 2022","first_posted":"June 13, 2013","results_first_posted":"March 13, 2017","last_update_posted":"November 1, 2021"},{"nctid":"NCT01876784","version_a":26,"version_b":27,"version_a_date":"2016-03-18","version_b_date":"2017-01-23","pom_a":[{"label":"1.","content":"Determination of the efficacy (as assessed by progression-free survival) of vandetanib when compared to placebo in the patient population[ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow-up). RECIST measurements taken every 12 weeks from randomization ]Once 155 progression events have occurred."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization until disease progression or death, assessed every 12 weeks (up to 22 months) ]The PFS was defined as the time (in months) from randomization until the date of first documented disease progression or death (from any cause), whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) was defined as: at least a 20% increase and absolute increase of 5 mm in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Analysis was performed by Kaplan-Meier method."}],"start_date":"September 17, 2013","primary_completion_date":"August 30, 2015","completion_date":"December 31, 2022","first_posted":"June 13, 2013","results_first_posted":"March 13, 2017","last_update_posted":"November 1, 2021"},{"nctid":"NCT01414608","version_a":60,"version_b":61,"version_a_date":"2014-02-27","version_b_date":"2014-03-25","pom_a":[{"label":"1.","content":"Overall survival rate at 5 years"}],"pom_b":[{"label":"1.","content":"Overall survival rate[ Time Frame: At 5 years ]Described with Kaplan-Meier curves and unadjusted logrank tests."}],"start_date":"January 9, 2012","primary_completion_date":"July 9, 2022","completion_date":"July 9, 2022","first_posted":"August 11, 2011","last_update_posted":"August 9, 2021"},{"nctid":"NCT01414608","version_a":70,"version_b":71,"version_a_date":"2016-10-26","version_b_date":"2017-05-02","pom_a":[{"label":"1.","content":"Overall survival rate[ Time Frame: At 5 years ]Described with Kaplan-Meier curves and unadjusted logrank tests."}],"pom_b":[{"label":"1.","content":"Overall survival rate[ Time Frame: From randomization to death from any cause, assessed at 5 years ]Described with Kaplan-Meier curves and unadjusted logrank tests."}],"start_date":"January 9, 2012","primary_completion_date":"July 9, 2022","completion_date":"July 9, 2022","first_posted":"August 11, 2011","last_update_posted":"August 9, 2021"},{"nctid":"NCT04818671","version_a":1,"version_b":2,"version_a_date":"2021-03-25","version_b_date":"2021-05-25","pom_a":[{"label":"1.","content":"Incidence and severity of Adverse Events (AEs)[ Time Frame: Up to 2 years ]"},{"label":"2.","content":"Incidence of Serious Adverse Events (SAEs)[ Time Frame: Up to 2 years ]"}],"pom_b":[{"label":"1.","content":"Incidence and severity of Adverse Events (AEs)[ Time Frame: Up to 2 years ]"},{"label":"2.","content":"Incidence of Serious Adverse Events (SAEs)[ Time Frame: Up to 2 years ]"},{"label":"3.","content":"Incidence of Adverse Events of Special Interest (AESI)[ Time Frame: Up to 2 years ]"}],"start_date":"April 26, 2021","primary_completion_date":"April 30, 2023","completion_date":"April 30, 2023","first_posted":"March 26, 2021","last_update_posted":"July 6, 2022"},{"nctid":"NCT02872116","version_a":11,"version_b":12,"version_a_date":"2017-01-05","version_b_date":"2017-01-19","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in subjects with programmed cell death ligand 1 (PD-L1) expressing tumors[ Time Frame: Approximately 35 months after the first patient is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in patients with programmed cell death ligand 1 (PD-L1) expressing tumors[ Time Frame: Approximately 40 months after the first patient is randomized ]"},{"label":"2.","content":"OS of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in patients with PD-L1 expressing tumors[ Time Frame: Approximately 40 months after the first patient is randomized ]"}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT02872116","version_a":35,"version_b":36,"version_a_date":"2018-01-17","version_b_date":"2018-02-12","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in patients with programmed cell death ligand 1 (PD-L1) expressing tumors[ Time Frame: Approximately 40 months after the first patient is randomized ]"},{"label":"2.","content":"OS of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in patients with PD-L1 expressing tumors[ Time Frame: Approximately 40 months after the first patient is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in participants with programmed cell death ligand 1 (PD-L1) expressing tumors[ Time Frame: Approximately 40 months after the first participant is randomized ]"},{"label":"2.","content":"OS of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in all randomized participants[ Time Frame: Approximately 40 months after the first participant is randomized ]"},{"label":"3.","content":"Objective Response Rate (ORR), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in all randomized participants[ Time Frame: Up to 40 months after the first participant is randomized ]"},{"label":"4.","content":"Progression-free Survival (PFS), as assessed by BICR, of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in all randomized participants[ Time Frame: Up to 40 months after the first participant is randomized ]"}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT02872116","version_a":51,"version_b":52,"version_a_date":"2018-09-24","version_b_date":"2018-11-05","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab + ipilimumab versus oxaliplatin + fluoropyrimidine in participants with programmed cell death ligand 1 (PD-L1) expressing tumors[ Time Frame: Approximately 40 months after the first participant is randomized ]"},{"label":"2.","content":"OS of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in all randomized participants[ Time Frame: Approximately 40 months after the first participant is randomized ]"},{"label":"3.","content":"Objective Response Rate (ORR), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in all randomized participants[ Time Frame: Up to 40 months after the first participant is randomized ]"},{"label":"4.","content":"Progression-free Survival (PFS), as assessed by BICR, of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in all randomized participants[ Time Frame: Up to 40 months after the first participant is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT02872116","version_a":52,"version_b":53,"version_a_date":"2018-11-05","version_b_date":"2018-12-06","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT02872116","version_a":74,"version_b":75,"version_a_date":"2020-09-09","version_b_date":"2021-05-19","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 53 months after the first participant is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 41 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 41 months after the first participant is randomized ]"}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT02872116","version_a":76,"version_b":77,"version_a_date":"2021-05-27","version_b_date":"2022-06-23","pom_a":[{"label":"1.","content":"Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants[ Time Frame: Up to 41 months after the first participant is randomized ]"},{"label":"2.","content":"Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in PD-L1 positive participants[ Time Frame: Up to 41 months after the first participant is randomized ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS \u2265 5[ Time Frame: From the date of randomization up to the date of death, up to approximately 17 months ]Overall survival (OS), defined as the time from randomization to the time of death, in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS (combined positive score) \u2265 5. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100."},{"label":"2.","content":"Progression Free Survival (PFS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS \u2265 5[ Time Frame: From randomization to the date of the first documented progressive disease (PD) per BICR or death due to any cause (up to approximately 10 months) ]Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented PD or death due to any cause. PD is determined by blinded independent committee review (BICR) per RECIST1.1 criteria in participants treated with Nivolumab plus Chemotherapy vs Chemotherapy with PD-L1 CPS \u2265 5. Progressive disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking in reference the smallest sum on study that also demonstrated an absolute increase of at least 5 mm. CPS is defined as the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100."}],"start_date":"October 12, 2016","primary_completion_date":"May 27, 2020","completion_date":"May 31, 2024","first_posted":"August 19, 2016","results_first_posted":"June 28, 2022","last_update_posted":"September 7, 2022"},{"nctid":"NCT00009945","version_a":11,"version_b":12,"version_a_date":"2009-02-06","version_b_date":"2009-09-29","pom_a":[],"pom_b":[{"label":"1.","content":"Disease free survival[ Time Frame: Time from randomization to breast cancer recurrence, second primary cancer, or death from any cause ]"}],"start_date":"January 2001","primary_completion_date":"March 2011","completion_date":"December 2012","first_posted":"January 27, 2003","results_first_posted":"November 20, 2017","last_update_posted":"December 13, 2017"},{"nctid":"NCT00009945","version_a":17,"version_b":18,"version_a_date":"2014-04-02","version_b_date":"2017-10-17","pom_a":[{"label":"1.","content":"Disease free survival[ Time Frame: Time from randomization to breast cancer recurrence, second primary cancer, or death from any cause ]"}],"pom_b":[{"label":"1.","content":"Disease Free Survival.[ Time Frame: 8 years ]Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years"}],"start_date":"January 2001","primary_completion_date":"March 2011","completion_date":"December 2012","first_posted":"January 27, 2003","results_first_posted":"November 20, 2017","last_update_posted":"December 13, 2017"},{"nctid":"NCT02504372","version_a":37,"version_b":38,"version_a_date":"2018-05-11","version_b_date":"2018-09-10","pom_a":[{"label":"1.","content":"Disease-free Survival (DFS)[ Time Frame: Up to 100 months ]"}],"pom_b":[{"label":"1.","content":"Disease-free Survival (DFS)[ Time Frame: Up to 77 months ]"}],"start_date":"November 6, 2015","primary_completion_date":"August 19, 2021","completion_date":"February 2, 2024","first_posted":"July 21, 2015","last_update_posted":"July 17, 2020"},{"nctid":"NCT02504372","version_a":41,"version_b":42,"version_a_date":"2019-11-27","version_b_date":"2020-07-15","pom_a":[{"label":"1.","content":"Disease-free Survival (DFS)[ Time Frame: Up to 77 months ]"}],"pom_b":[{"label":"1.","content":"Disease-free Survival (DFS)[ Time Frame: Up to approximately 78 months ]"}],"start_date":"November 6, 2015","primary_completion_date":"August 19, 2021","completion_date":"February 2, 2024","first_posted":"July 21, 2015","last_update_posted":"July 17, 2020"},{"nctid":"NCT00017147","version_a":15,"version_b":16,"version_a_date":"2005-11-23","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Survival"}],"start_date":"September 2001","primary_completion_date":"May 2006","completion_date":"November 2012","first_posted":"January 27, 2003","last_update_posted":"January 30, 2013"},{"nctid":"NCT00017147","version_a":26,"version_b":27,"version_a_date":"2011-07-19","version_b_date":"2012-01-12","pom_a":[{"label":"1.","content":"Survival"}],"pom_b":[{"label":"1.","content":"Survival[ Time Frame: assessed every 6 weeks for 42 weeks, then every 4 months for one year, followed by every 6 months for years 2 through 5 ]"}],"start_date":"September 2001","primary_completion_date":"May 2006","completion_date":"November 2012","first_posted":"January 27, 2003","last_update_posted":"January 30, 2013"},{"nctid":"NCT00254904","version_a":25,"version_b":26,"version_a_date":"2007-08-20","version_b_date":"2007-12-19","pom_a":[{"label":"1.","content":"Overall Survival"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: 656 Events ]"}],"start_date":"November 2005","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"November 17, 2005","last_update_posted":"March 30, 2015"},{"nctid":"NCT00063882","version_a":50,"version_b":51,"version_a_date":"2006-11-16","version_b_date":"2006-11-21","pom_a":[],"pom_b":[{"label":"1.","content":"Compare overall survival at eight years"}],"start_date":"June 2003","primary_completion_date":"May 2017","first_posted":"July 9, 2003","results_first_posted":"October 16, 2019","last_update_posted":"November 5, 2021"},{"nctid":"NCT00063882","version_a":52,"version_b":53,"version_a_date":"2006-11-27","version_b_date":"2006-12-06","pom_a":[{"label":"1.","content":"Compare overall survival at eight years"}],"pom_b":[{"label":"1.","content":"Overall survival at 8 years"}],"start_date":"June 2003","primary_completion_date":"May 2017","first_posted":"July 9, 2003","results_first_posted":"October 16, 2019","last_update_posted":"November 5, 2021"},{"nctid":"NCT00063882","version_a":145,"version_b":146,"version_a_date":"2008-02-29","version_b_date":"2008-03-01","pom_a":[{"label":"1.","content":"Overall survival at 8 years"}],"pom_b":[{"label":"1.","content":"Freedom from progression"}],"start_date":"June 2003","primary_completion_date":"May 2017","first_posted":"July 9, 2003","results_first_posted":"October 16, 2019","last_update_posted":"November 5, 2021"},{"nctid":"NCT00063882","version_a":460,"version_b":461,"version_a_date":"2012-08-03","version_b_date":"2014-05-21","pom_a":[{"label":"1.","content":"Freedom from progression"}],"pom_b":[{"label":"1.","content":"Freedom from progression[ Time Frame: From randomization to the first occurrence of biochemical failure, clinical failure (local or distant), death from any cause, or last follow-up. Analysis occurs after all patients have been potentially followed for 5 years. ]"}],"start_date":"June 2003","primary_completion_date":"May 2017","first_posted":"July 9, 2003","results_first_posted":"October 16, 2019","last_update_posted":"November 5, 2021"},{"nctid":"NCT00063882","version_a":464,"version_b":465,"version_a_date":"2017-05-18","version_b_date":"2019-09-25","pom_a":[{"label":"1.","content":"Freedom from progression[ Time Frame: From randomization to the first occurrence of biochemical failure, clinical failure (local or distant), death from any cause, or last follow-up. Analysis occurs after all patients have been potentially followed for 5 years. ]"}],"pom_b":[{"label":"1.","content":"5-Year Freedom From Progression Rate[ Time Frame: From randomization to 5 years ]A Freedom from Progression (FFP) failure includes biochemical failure, local failure, distant failure, or death due to any cause. Patients who are failure free with less than 5 years of follow-up or who receive any secondary salvage therapy are censored. Freedom from Progression rates are estimated using the Kaplan-Meier method."}],"start_date":"June 2003","primary_completion_date":"May 2017","first_posted":"July 9, 2003","results_first_posted":"October 16, 2019","last_update_posted":"November 5, 2021"},{"nctid":"NCT03258554","version_a":11,"version_b":12,"version_a_date":"2018-03-01","version_b_date":"2018-03-02","pom_a":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."},{"label":"3.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."}],"pom_b":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"label":"2.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."},{"label":"3.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."}],"start_date":"December 12, 2017","primary_completion_date":"December 31, 2025","completion_date":"December 31, 2025","first_posted":"August 23, 2017","last_update_posted":"September 7, 2022"},{"nctid":"NCT03258554","version_a":47,"version_b":48,"version_a_date":"2018-07-23","version_b_date":"2018-08-01","pom_a":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"label":"2.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."},{"label":"3.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."}],"pom_b":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy (RT) ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"label":"2.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."},{"label":"3.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."}],"start_date":"December 12, 2017","primary_completion_date":"December 31, 2025","completion_date":"December 31, 2025","first_posted":"August 23, 2017","last_update_posted":"September 7, 2022"},{"nctid":"NCT03258554","version_a":62,"version_b":63,"version_a_date":"2019-02-22","version_b_date":"2019-03-11","pom_a":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy (RT) ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."},{"label":"2.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."},{"label":"3.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."}],"pom_b":[{"label":"1.","content":"Dose-limiting toxicity (DLT) defined as the occurrence of an adverse event (AE) during the specified observation window (Lead -in)[ Time Frame: Up to 4 weeks after radiation therapy (RT) ]AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0."},{"label":"2.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization until first evidence of local, regional, or distant disease progression or recurrence, or death from any cause, assessed up to 3 years ]PFS will be estimated using the Kaplan-Meier method. The difference in PFS between the two arms will be tested using a log-rank test."},{"label":"3.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization until death from any cause, assessed up to 3 years ]OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models."}],"start_date":"December 12, 2017","primary_completion_date":"December 31, 2025","completion_date":"December 31, 2025","first_posted":"August 23, 2017","last_update_posted":"September 7, 2022"},{"nctid":"NCT02562755","version_a":50,"version_b":51,"version_a_date":"2019-08-08","version_b_date":"2020-12-11","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: From the date of randomization to the date of death due to any cause up to study completion (approximately 53 months). ]"}],"pom_b":[{"label":"1.","content":"Overall Response Rate (ORR)[ Time Frame: From date of randomization to the date of first documented radiographic tumor progression up to 53 months ]Percentage of participants who showed overall response during their participation in the study. Per Modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST) and assessed by tri-phasic contrast enhanced CT: Complete Response (CR), Disappearance of intratumoral enhancing area; Partial Response (PR), >=30% decrease in the sum of the diameters of enhancing area; Overall Response (OR) = CR + PR."}],"start_date":"October 2015","primary_completion_date":"July 2020","completion_date":"July 2020","first_posted":"September 29, 2015","results_first_posted":"December 16, 2020","last_update_posted":"December 16, 2020"},{"nctid":"NCT02486718","version_a":21,"version_b":22,"version_a_date":"2016-10-03","version_b_date":"2017-02-28","pom_a":[{"label":"1.","content":"Disease-Free Survival (DFS)[ Time Frame: up to 47 months ]"}],"pom_b":[{"label":"1.","content":"DFS, Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray in in Stage IB-IIIA (Intent-to-Treat [ITT]) Population[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]"},{"label":"2.","content":"DFS, Assessed Using CT/MRI/X-Ray in Stage II-IIIA and PD-L1-Selected Subpopulation[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]"}],"start_date":"October 31, 2015","primary_completion_date":"December 1, 2023","completion_date":"December 17, 2027","first_posted":"July 1, 2015","last_update_posted":"August 15, 2022"},{"nctid":"NCT02486718","version_a":47,"version_b":48,"version_a_date":"2019-01-07","version_b_date":"2019-01-29","pom_a":[{"label":"1.","content":"DFS, Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray in in Stage IB-IIIA (Intent-to-Treat [ITT]) Population[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]"},{"label":"2.","content":"DFS, Assessed Using CT/MRI/X-Ray in Stage II-IIIA and PD-L1-Selected Subpopulation[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]"}],"pom_b":[{"label":"1.","content":"Disease-Free Survival (DFS), Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]DFS will be assessed by the investigator in PD-L1-selected populations within the Stage II-IIIA subpopulation, in all randomized Stage II-IIIA participants, and in the intent-to-treat (ITT) population."}],"start_date":"October 31, 2015","primary_completion_date":"December 1, 2023","completion_date":"December 17, 2027","first_posted":"July 1, 2015","last_update_posted":"August 15, 2022"},{"nctid":"NCT02486718","version_a":57,"version_b":58,"version_a_date":"2020-08-17","version_b_date":"2020-10-01","pom_a":[{"label":"1.","content":"Disease-Free Survival (DFS), Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]DFS will be assessed by the investigator in PD-L1-selected populations within the Stage II-IIIA subpopulation, in all randomized Stage II-IIIA participants, and in the intent-to-treat (ITT) population."}],"pom_b":[{"label":"1.","content":"Disease-Free Survival (DFS), Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray[ Time Frame: From randomization to the date of first recurrence of NSCLC, occurrence of new primary NSCLC, or death from any cause, whichever occurs first (up to approximately 131 months) ]DFS will be assessed by the investigator in PD-L1 subpopulation within the Stage II-IIIA population, in all randomized patients with Stage II-IIIA NSCLC, and in the ITT population."}],"start_date":"October 31, 2015","primary_completion_date":"December 1, 2023","completion_date":"December 17, 2027","first_posted":"July 1, 2015","last_update_posted":"August 15, 2022"},{"nctid":"NCT00557193","version_a":278,"version_b":279,"version_a_date":"2012-11-20","version_b_date":"2013-07-03","pom_a":[{"label":"1.","content":"Event-free survival at 3 years"}],"pom_b":[{"label":"1.","content":"Event-free survival of MLL-R infants randomized to a modified P9407 backbone with or without lestaurtinib[ Time Frame: At 3 years ]All randomized patients will be included in the intent-to-treat efficacy analyses. Event-free survival time will be calculated from the time of randomization, which is just prior to beginning Induction Intensification."}],"start_date":"January 14, 2008","primary_completion_date":"September 30, 2017","completion_date":"July 20, 2023","first_posted":"November 12, 2007","results_first_posted":"December 10, 2018","last_update_posted":"September 13, 2022"},{"nctid":"NCT00557193","version_a":282,"version_b":283,"version_a_date":"2014-06-30","version_b_date":"2014-08-20","pom_a":[{"label":"1.","content":"Event-free survival of MLL-R infants randomized to a modified P9407 backbone with or without lestaurtinib[ Time Frame: At 3 years ]All randomized patients will be included in the intent-to-treat efficacy analyses. Event-free survival time will be calculated from the time of randomization, which is just prior to beginning Induction Intensification."}],"pom_b":[{"label":"1.","content":"Lestaurtinib-related dose limiting toxicity as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: Up to 12 weeks ]"},{"label":"2.","content":"Event-free survival (EFS) of MLL-R infants randomized to combination chemotherapy with or without lestaurtinib[ Time Frame: At 3 years ]All randomized patients will be included in the intent-to-treat efficacy analyses. EFS will be calculated from the time of randomization, which is just prior to beginning Induction Intensification. A 1-sided log rank test will be used to compare EFS between the 2 arms."},{"label":"3.","content":"EFS of patients treated on Arm C[ Time Frame: At 3 years ]A one-sided 95% confidence interval for EFS will be constructed."}],"start_date":"January 14, 2008","primary_completion_date":"September 30, 2017","completion_date":"July 20, 2023","first_posted":"November 12, 2007","results_first_posted":"December 10, 2018","last_update_posted":"September 13, 2022"},{"nctid":"NCT00557193","version_a":287,"version_b":288,"version_a_date":"2018-07-13","version_b_date":"2018-09-10","pom_a":[{"label":"1.","content":"Lestaurtinib-related dose limiting toxicity as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: Up to 12 weeks ]"},{"label":"2.","content":"Event-free survival (EFS) of MLL-R infants randomized to combination chemotherapy with or without lestaurtinib[ Time Frame: At 3 years ]All randomized patients will be included in the intent-to-treat efficacy analyses. EFS will be calculated from the time of randomization, which is just prior to beginning Induction Intensification. A 1-sided log rank test will be used to compare EFS between the 2 arms."},{"label":"3.","content":"EFS of patients treated on Arm C[ Time Frame: At 3 years ]A one-sided 95% confidence interval for EFS will be constructed."}],"pom_b":[{"label":"1.","content":"EFS of patients treated on Arm C at dose level 2 (DL2) (chemotherapy plus the FLT3 inhibitor lestaurtinib)[ Time Frame: At 3 years ]A one-sided 95% confidence interval for EFS at 3 years will be constructed to measure the EFS of patients in Arm C at dose level 2 (DL2)."}],"start_date":"January 14, 2008","primary_completion_date":"September 30, 2017","completion_date":"July 20, 2023","first_posted":"November 12, 2007","results_first_posted":"December 10, 2018","last_update_posted":"September 13, 2022"},{"nctid":"NCT00557193","version_a":288,"version_b":289,"version_a_date":"2018-09-10","version_b_date":"2018-11-13","pom_a":[{"label":"1.","content":"EFS of patients treated on Arm C at dose level 2 (DL2) (chemotherapy plus the FLT3 inhibitor lestaurtinib)[ Time Frame: At 3 years ]A one-sided 95% confidence interval for EFS at 3 years will be constructed to measure the EFS of patients in Arm C at dose level 2 (DL2)."}],"pom_b":[{"label":"1.","content":"Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)[ Time Frame: From start of post-induction therapy for up to 10 years ]EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto."}],"start_date":"January 14, 2008","primary_completion_date":"September 30, 2017","completion_date":"July 20, 2023","first_posted":"November 12, 2007","results_first_posted":"December 10, 2018","last_update_posted":"September 13, 2022"},{"nctid":"NCT01774786","version_a":102,"version_b":103,"version_a_date":"2016-08-01","version_b_date":"2016-09-29","pom_a":[{"label":"1.","content":"Overall survival: Time from randomization to death of any cause[ Time Frame: approximately 4.5 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline up to death (up to approximately 8.5 years) ]"}],"start_date":"June 10, 2013","primary_completion_date":"December 9, 2016","completion_date":"December 31, 2019","first_posted":"January 24, 2013","results_first_posted":"February 14, 2018","last_update_posted":"December 30, 2020"},{"nctid":"NCT01774786","version_a":109,"version_b":110,"version_a_date":"2017-11-02","version_b_date":"2018-01-17","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline up to death (up to approximately 8.5 years) ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline up to death (up to the 09 Dec 2016 data cutoff, approximately 3.5 years) ]Overall survival (OS) was defined as the time from randomization to death from any cause."}],"start_date":"June 10, 2013","primary_completion_date":"December 9, 2016","completion_date":"December 31, 2019","first_posted":"January 24, 2013","results_first_posted":"February 14, 2018","last_update_posted":"December 30, 2020"},{"nctid":"NCT01774786","version_a":121,"version_b":122,"version_a_date":"2020-05-21","version_b_date":"2020-12-03","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Baseline up to death (up to the 09 Dec 2016 data cutoff, approximately 3.5 years) ]Overall survival (OS) was defined as the time from randomization to death from any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months) ]Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day."}],"start_date":"June 10, 2013","primary_completion_date":"December 9, 2016","completion_date":"December 31, 2019","first_posted":"January 24, 2013","results_first_posted":"February 14, 2018","last_update_posted":"December 30, 2020"},{"nctid":"NCT03470922","version_a":12,"version_b":13,"version_a_date":"2018-08-27","version_b_date":"2018-09-24","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to 5 years ]Phase 3 portion of trial. Assessed by a Blinded Independent Central Review (BICR)"},{"label":"2.","content":"Overall Response Rate (ORR)[ Time Frame: Up to 5 years ]Phase 2 portion of trial, assessed by a BICR"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to 5 years ]Phase 3 portion of trial. Assessed by a Blinded Independent Central Review (BICR)"},{"label":"2.","content":"PFS[ Time Frame: Up to 5 years ]Phase 2 portion of trial, assessed by a BICR"}],"start_date":"April 11, 2018","primary_completion_date":"January 25, 2021","completion_date":"November 30, 2023","first_posted":"March 20, 2018","results_first_posted":"March 29, 2022","last_update_posted":"March 29, 2022"},{"nctid":"NCT03470922","version_a":36,"version_b":37,"version_a_date":"2020-08-31","version_b_date":"2021-07-08","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to 5 years ]Phase 3 portion of trial. Assessed by a Blinded Independent Central Review (BICR)"},{"label":"2.","content":"PFS[ Time Frame: Up to 5 years ]Phase 2 portion of trial, assessed by a BICR"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1[ Time Frame: Up to approximately 32 months ]"}],"start_date":"April 11, 2018","primary_completion_date":"January 25, 2021","completion_date":"November 30, 2023","first_posted":"March 20, 2018","results_first_posted":"March 29, 2022","last_update_posted":"March 29, 2022"},{"nctid":"NCT03470922","version_a":37,"version_b":38,"version_a_date":"2021-07-08","version_b_date":"2022-01-25","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1[ Time Frame: Up to approximately 32 months ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: From randomization to date of first documented tumor progression or death (up to approximately 33 months) ]Progression Free Survival (PFS) is defined as the time between the date of randomization and the date of first documented tumor progression, assessed by a blinded independent central review (BICR) (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Subjects who die without a reported progression will be considered to have progressed on the date of their death."}],"start_date":"April 11, 2018","primary_completion_date":"January 25, 2021","completion_date":"November 30, 2023","first_posted":"March 20, 2018","results_first_posted":"March 29, 2022","last_update_posted":"March 29, 2022"},{"nctid":"NCT04222972","version_a":7,"version_b":8,"version_a_date":"2021-04-26","version_b_date":"2021-05-26","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Estimated at up to 32 months ]Defined as the number of weeks from randomization date to the earlier of documented progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 central imaging review or death due to any cause"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Estimated at up to 32 months ]Defined as the time from randomisation date to the first documented progressive disease (PD), as assessed by Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 central imaging review or death due to any cause, whichever occurs first."}],"start_date":"July 24, 2020","primary_completion_date":"September 30, 2023","completion_date":"December 31, 2024","first_posted":"January 10, 2020","last_update_posted":"September 6, 2022"},{"nctid":"NCT00043927","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2006-03-06","pom_a":[],"pom_b":[{"label":"1.","content":"Overall Survival"}],"start_date":"April 2001","primary_completion_date":"January 2004","first_posted":"August 16, 2002","last_update_posted":"August 21, 2013"},{"nctid":"NCT00471445","version_a":1,"version_b":2,"version_a_date":"2007-05-08","version_b_date":"2007-05-16","pom_a":[{"label":"1.","content":"Change in average daily pain intensity score in amitriptyline and ketamine hydrochloride group and placebo group from baseline to day 84"}],"pom_b":[{"label":"1.","content":"Change in average daily pain intensity score from baseline to day 84 in patients treated with amitriptyline and ketamine hydrochloride vs placebo"}],"start_date":"October 2007","primary_completion_date":"September 2013","completion_date":"November 2013","first_posted":"May 10, 2007","results_first_posted":"June 10, 2015","last_update_posted":"November 9, 2015"},{"nctid":"NCT00471445","version_a":19,"version_b":20,"version_a_date":"2008-11-07","version_b_date":"2008-11-22","pom_a":[{"label":"1.","content":"Change in average daily pain intensity score from baseline to day 84 in patients treated with amitriptyline and ketamine hydrochloride vs placebo"}],"pom_b":[{"label":"1.","content":"Change in average daily peripheral neuropathy intensity score from baseline to week 6 in patients treated with amitriptyline and ketamine hydrochloride vs placebo"}],"start_date":"October 2007","primary_completion_date":"September 2013","completion_date":"November 2013","first_posted":"May 10, 2007","results_first_posted":"June 10, 2015","last_update_posted":"November 9, 2015"},{"nctid":"NCT00471445","version_a":31,"version_b":32,"version_a_date":"2010-09-28","version_b_date":"2010-11-08","pom_a":[{"label":"1.","content":"Change in average daily peripheral neuropathy intensity score from baseline to week 6 in patients treated with amitriptyline and ketamine hydrochloride vs placebo"}],"pom_b":[{"label":"1.","content":"Change in average daily peripheral neuropathy intensity score from baseline to week 6 in patients treated with amitriptyline and ketamine hydrochloride vs placebo[ Time Frame: 6 weeks ]"}],"start_date":"October 2007","primary_completion_date":"September 2013","completion_date":"November 2013","first_posted":"May 10, 2007","results_first_posted":"June 10, 2015","last_update_posted":"November 9, 2015"},{"nctid":"NCT00471445","version_a":37,"version_b":38,"version_a_date":"2014-01-31","version_b_date":"2015-06-08","pom_a":[{"label":"1.","content":"Change in average daily peripheral neuropathy intensity score from baseline to week 6 in patients treated with amitriptyline and ketamine hydrochloride vs placebo[ Time Frame: 6 weeks ]"}],"pom_b":[{"label":"1.","content":"Change in Average Daily Peripheral Neuropathy Intensity Score From Baseline to Week 6 in Patients Treated With Amitriptyline and Ketamine Hydrochloride vs Placebo[ Time Frame: Week 6 - Baseline ]Cancer survivors who completed chemotherapy at least 1 month prior and had Chemotherapy Induced Peripheral Neuropathy (CIPN) (greater than or equal to 4 out of 10) were enrolled. CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average \\"pain, numbness, or tingling in their hands and feet over the past 24 hours\\" on an 11-point numeric rating scale at baseline and 6 weeks post intervention. CIPN ranges from 0 (no pain) to 10 (worst possible pain)."}],"start_date":"October 2007","primary_completion_date":"September 2013","completion_date":"November 2013","first_posted":"May 10, 2007","results_first_posted":"June 10, 2015","last_update_posted":"November 9, 2015"},{"nctid":"NCT02595944","version_a":135,"version_b":136,"version_a_date":"2017-02-01","version_b_date":"2017-02-17","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer confirmed by biopsy, or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all s"},{"label":"2.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stra"}],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all s"},{"label":"2.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stra"}],"start_date":"May 6, 2016","primary_completion_date":"September 1, 2025","completion_date":"September 1, 2025","first_posted":"November 4, 2015","last_update_posted":"September 6, 2022"},{"nctid":"NCT02595944","version_a":358,"version_b":359,"version_a_date":"2018-02-13","version_b_date":"2018-02-15","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all s"},{"label":"2.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stra"}],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"start_date":"May 6, 2016","primary_completion_date":"September 1, 2025","completion_date":"September 1, 2025","first_posted":"November 4, 2015","last_update_posted":"September 6, 2022"},{"nctid":"NCT02595944","version_a":368,"version_b":369,"version_a_date":"2018-03-01","version_b_date":"2018-03-02","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"start_date":"May 6, 2016","primary_completion_date":"September 1, 2025","completion_date":"September 1, 2025","first_posted":"November 4, 2015","last_update_posted":"September 6, 2022"},{"nctid":"NCT02595944","version_a":405,"version_b":406,"version_a_date":"2018-05-14","version_b_date":"2018-05-31","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Disease-free survival[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"start_date":"May 6, 2016","primary_completion_date":"September 1, 2025","completion_date":"September 1, 2025","first_posted":"November 4, 2015","last_update_posted":"September 6, 2022"},{"nctid":"NCT02595944","version_a":560,"version_b":561,"version_a_date":"2019-02-27","version_b_date":"2019-03-11","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 2.0% for OS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to the earliest event defined as disease any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate of 0.5% for DFS. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"pom_b":[{"label":"1.","content":"Disease-free survival (DFS)[ Time Frame: Time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years ]DFS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of DFS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate corresponding to the significance level associated with population being analyzed; that is, 1.5% for the overall population and 1% for the >= 50% population. The latter test will only be performed in the event that the primary test in all-comers is not statistically significant. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Time from randomization to death from any cause, assessed up to 10 years ]OS distributions will be estimated using the Kaplan-Meier method, and Cox proportional hazards models will be used to estimate the treatment hazard ratios. The primary comparisons of OS will use a logrank tests stratified on the randomization stratification factors with a one-sided type I error rate corresponding to the significance level associated with population being analyzed; that is, 1.5% for the overall population and 1% for the >= 50% population. The latter test will only be performed in the event that the primary test in all-comers is not statistically significant. Other comparisons of groups will be made using the logrank test and Cox modeling. Point estimates of all endpoints will be accompanied by the corresponding confidence intervals adjusted for the type I error rates associated with the endpoint. Subset analyses are planned for all stratification factors and all known prognostic factors such as performance status, age, gender, etc."}],"start_date":"May 6, 2016","primary_completion_date":"September 1, 2025","completion_date":"September 1, 2025","first_posted":"November 4, 2015","last_update_posted":"September 6, 2022"},{"nctid":"NCT02685605","version_a":2,"version_b":3,"version_a_date":"2016-02-19","version_b_date":"2016-05-12","pom_a":[{"label":"1.","content":"Median Progression-Free Survival[ Time Frame: 24 Months ]Determined according to updated Response Assessment in Neuro-Oncology (RANO) criteria"}],"pom_b":[{"label":"1.","content":"Median Progression-Free Survival[ Time Frame: 24 Months ]Determined according to modified Response Assessment in Neuro-Oncology (RANO) criteria and serial perfusion imaging"}],"start_date":"December 9, 2016","primary_completion_date":"December 2023","completion_date":"March 2024","first_posted":"February 19, 2016","last_update_posted":"May 18, 2022"},{"nctid":"NCT01605227","version_a":30,"version_b":31,"version_a_date":"2015-04-13","version_b_date":"2018-02-14","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Through 21 months after study start ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: OS was measured from the time of randomization until 614 events, approximately 24 months after study start ]The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred."}],"start_date":"July 2012","primary_completion_date":"September 2014","completion_date":"March 2015","first_posted":"May 24, 2012","results_first_posted":"March 14, 2018","last_update_posted":"March 14, 2018"},{"nctid":"NCT00689936","version_a":3,"version_b":4,"version_a_date":"2009-04-02","version_b_date":"2009-08-13","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: 01April 2010 ]"}],"start_date":"August 21, 2008","primary_completion_date":"July 14, 2016","completion_date":"July 14, 2016","first_posted":"June 4, 2008","results_first_posted":"August 11, 2017","last_update_posted":"November 20, 2019"},{"nctid":"NCT00689936","version_a":8,"version_b":9,"version_a_date":"2011-09-07","version_b_date":"2013-08-26","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: 01April 2010 ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 436 weeks ]Time from randomization to the first documentation of disease progression."}],"start_date":"August 21, 2008","primary_completion_date":"July 14, 2016","completion_date":"July 14, 2016","first_posted":"June 4, 2008","results_first_posted":"August 11, 2017","last_update_posted":"November 20, 2019"},{"nctid":"NCT00689936","version_a":18,"version_b":19,"version_a_date":"2016-10-28","version_b_date":"2017-07-13","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 436 weeks ]Time from randomization to the first documentation of disease progression."}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)[ Time Frame: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months. ]PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment\'s)."},{"label":"2.","content":"Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis[ Time Frame: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months ]PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment\'s)."}],"start_date":"August 21, 2008","primary_completion_date":"July 14, 2016","completion_date":"July 14, 2016","first_posted":"June 4, 2008","results_first_posted":"August 11, 2017","last_update_posted":"November 20, 2019"},{"nctid":"NCT00002593","version_a":13,"version_b":14,"version_a_date":"2011-12-17","version_b_date":"2013-01-02","pom_a":[],"pom_b":[{"label":"1.","content":"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival[ Time Frame: At death ]"}],"start_date":"December 1994","primary_completion_date":"December 1999","completion_date":"March 2005","first_posted":"August 31, 2004","last_update_posted":"January 3, 2013"},{"nctid":"NCT03456063","version_a":18,"version_b":19,"version_a_date":"2019-02-04","version_b_date":"2019-02-21","pom_a":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."}],"pom_b":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Investigator-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 84 months ]EFS is defined as the time from the date of randomization to any of the following events, whichever occurs first: progression of disease that precludes surgery per RECIST v1.1, as assessed by the investigator; local or distant disease recurrence, as assessed by the investigator; or death due to any cause."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03456063","version_a":33,"version_b":34,"version_a_date":"2020-01-06","version_b_date":"2020-01-21","pom_a":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Investigator-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 84 months ]EFS is defined as the time from the date of randomization to any of the following events, whichever occurs first: progression of disease that precludes surgery per RECIST v1.1, as assessed by the investigator; local or distant disease recurrence, as assessed by the investigator; or death due to any cause."}],"pom_b":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 84 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the IRF; or death from any cause, whichever occurs first."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03456063","version_a":40,"version_b":41,"version_a_date":"2020-06-01","version_b_date":"2020-07-08","pom_a":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 84 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the IRF; or death from any cause, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 73 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03456063","version_a":49,"version_b":50,"version_a_date":"2021-01-20","version_b_date":"2021-01-22","pom_a":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 73 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 70 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03456063","version_a":52,"version_b":53,"version_a_date":"2021-03-05","version_b_date":"2021-03-24","pom_a":[{"label":"1.","content":"Major pathological response (MPR)[ Time Frame: At time of surgery ]MPR is defined as \u2264 10% residual viable tumor at the time of surgical resection, as assessed by central pathology laboratory."},{"label":"2.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Approximately 70 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Up to approximately 81 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT03456063","version_a":58,"version_b":59,"version_a_date":"2021-08-04","version_b_date":"2021-09-15","pom_a":[{"label":"1.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Up to approximately 81 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)[ Time Frame: Up to approximately 96 months ]IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first."}],"start_date":"April 24, 2018","primary_completion_date":"November 20, 2024","completion_date":"November 20, 2024","first_posted":"March 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT00223145","version_a":1,"version_b":2,"version_a_date":"2005-09-15","version_b_date":"2006-03-17","pom_a":[{"label":"1.","content":"Interval before biochemical failure."},{"label":"2.","content":"Disease-free survival."}],"pom_b":[{"label":"1.","content":"Interval before biochemical failure"},{"label":"2.","content":"Disease-free survival"}],"start_date":"December 2000","primary_completion_date":"December 31, 2023","completion_date":"December 31, 2023","first_posted":"September 22, 2005","last_update_posted":"May 23, 2022"},{"nctid":"NCT00223145","version_a":3,"version_b":4,"version_a_date":"2006-09-13","version_b_date":"2013-07-18","pom_a":[{"label":"1.","content":"Interval before biochemical failure"},{"label":"2.","content":"Disease-free survival"}],"pom_b":[{"label":"1.","content":"Interval before biochemical failure[ Time Frame: 10 years ]"},{"label":"2.","content":"Disease-free survival[ Time Frame: 10 years ]"}],"start_date":"December 2000","primary_completion_date":"December 31, 2023","completion_date":"December 31, 2023","first_posted":"September 22, 2005","last_update_posted":"May 23, 2022"},{"nctid":"NCT00223145","version_a":6,"version_b":7,"version_a_date":"2015-01-22","version_b_date":"2017-05-09","pom_a":[{"label":"1.","content":"Interval before biochemical failure[ Time Frame: 10 years ]"},{"label":"2.","content":"Disease-free survival[ Time Frame: 10 years ]"}],"pom_b":[{"label":"1.","content":"Interval before biochemical failure[ Time Frame: 10 years ]"}],"start_date":"December 2000","primary_completion_date":"December 31, 2023","completion_date":"December 31, 2023","first_posted":"September 22, 2005","last_update_posted":"May 23, 2022"},{"nctid":"NCT03972488","version_a":12,"version_b":13,"version_a_date":"2021-08-26","version_b_date":"2021-10-15","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: through Week 72 until 99 PFS events are reached ]Time from randomization to the first line progression (centrally assessed according to RECIST 1.1)"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: through Week 72 until 99 PFS events are reached ]Time from randomization to the first line progression (centrally assessed according to RECIST 1.1 or death due to any cause)"}],"start_date":"January 22, 2020","primary_completion_date":"December 31, 2023","completion_date":"October 30, 2027","first_posted":"June 3, 2019","last_update_posted":"July 5, 2022"},{"nctid":"NCT00732914","version_a":4,"version_b":5,"version_a_date":"2010-10-18","version_b_date":"2012-03-09","pom_a":[{"label":"1.","content":"total Progression Free Survival[ Time Frame: Last patient last visit (LPLV) to Feb 2013 ]"}],"pom_b":[{"label":"1.","content":"total Progression Free Survival[ Time Frame: Last patient last visit (LPLV) to June 2013 ]"}],"start_date":"January 2009","primary_completion_date":"October 2013","completion_date":"December 2013","first_posted":"August 12, 2008","last_update_posted":"April 23, 2014"},{"nctid":"NCT00732914","version_a":5,"version_b":6,"version_a_date":"2012-03-09","version_b_date":"2014-04-22","pom_a":[{"label":"1.","content":"total Progression Free Survival[ Time Frame: Last patient last visit (LPLV) to June 2013 ]"}],"pom_b":[{"label":"1.","content":"total Progression Free Survival[ Time Frame: Last patient last visit (LPLV) to October 2013 ]"}],"start_date":"January 2009","primary_completion_date":"October 2013","completion_date":"December 2013","first_posted":"August 12, 2008","last_update_posted":"April 23, 2014"},{"nctid":"NCT00090220","version_a":3,"version_b":4,"version_a_date":"2005-09-27","version_b_date":"2006-01-12","pom_a":[],"pom_b":[{"label":"1.","content":"Combined incidence of HPV6/11/16/18 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer through Month 7."}],"start_date":"June 16, 2004","primary_completion_date":"May 21, 2009","completion_date":"November 12, 2015","first_posted":"August 27, 2004","results_first_posted":"February 1, 2010","last_update_posted":"April 21, 2017"},{"nctid":"NCT00090220","version_a":9,"version_b":10,"version_a_date":"2009-01-14","version_b_date":"2009-02-03","pom_a":[{"label":"1.","content":"Combined incidence of HPV6/11/16/18 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer through Month 7."}],"pom_b":[{"label":"1.","content":"Combined incidence of HPV6/11/16/18 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer[ Time Frame: 48 months ]"}],"start_date":"June 16, 2004","primary_completion_date":"May 21, 2009","completion_date":"November 12, 2015","first_posted":"August 27, 2004","results_first_posted":"February 1, 2010","last_update_posted":"April 21, 2017"},{"nctid":"NCT00090220","version_a":16,"version_b":17,"version_a_date":"2009-10-29","version_b_date":"2010-01-05","pom_a":[{"label":"1.","content":"Combined incidence of HPV6/11/16/18 related persistent infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia, cervical AIS, and cervical cancer[ Time Frame: 48 months ]"}],"pom_b":[{"label":"1.","content":"Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer[ Time Frame: Day 1 to Month 48 ]HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) associated with the primary outcome measure were determined by polymerase chain reaction (PCR) testing."}],"start_date":"June 16, 2004","primary_completion_date":"May 21, 2009","completion_date":"November 12, 2015","first_posted":"August 27, 2004","results_first_posted":"February 1, 2010","last_update_posted":"April 21, 2017"},{"nctid":"NCT00090220","version_a":18,"version_b":19,"version_a_date":"2010-06-14","version_b_date":"2012-08-14","pom_a":[{"label":"1.","content":"Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer[ Time Frame: Day 1 to Month 48 ]HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) associated with the primary outcome measure were determined by polymerase chain reaction (PCR) testing."}],"pom_b":[{"label":"1.","content":"Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer[ Time Frame: Base Study: through Month 48 ]HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) were determined by polymerase chain reaction (PCR) testing"},{"label":"2.","content":"Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)[ Time Frame: Base Study: through Month 48 ]"}],"start_date":"June 16, 2004","primary_completion_date":"May 21, 2009","completion_date":"November 12, 2015","first_posted":"August 27, 2004","results_first_posted":"February 1, 2010","last_update_posted":"April 21, 2017"},{"nctid":"NCT00090220","version_a":30,"version_b":31,"version_a_date":"2016-01-20","version_b_date":"2016-11-07","pom_a":[{"label":"1.","content":"Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer[ Time Frame: Base Study: through Month 48 ]HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) were determined by polymerase chain reaction (PCR) testing"},{"label":"2.","content":"Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)[ Time Frame: Base Study: through Month 48 ]"}],"pom_b":[{"label":"1.","content":"Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer[ Time Frame: Up to 48 months (4 years) after the first dose of qHPV vaccine in the Base Study ]The four HPV types were determined by polymerase chain reaction (PCR) testing. VIN = vulvar intraepithelial neoplasia; VaIN = vaginal intraepithelial neoplasia; AIS = adenocarcinoma in situ."},{"label":"2.","content":"Number of Participants With Vaccine- or Placebo-Related Serious Adverse Events (SAEs) in the Base Study[ Time Frame: Up to Month 48 (up to 42 months after the third dose of qHPV vaccine in the Base Study) ]An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose. Vaccine-related SAEs are those deemed by the investigator to be definitely, probably, or possibly related to study vaccine."},{"label":"3.","content":"Number of Participants With Vaccine-Related SAEs After Vaccine Administration[ Time Frame: qHPV in Base Study: Up to Month 120; Placebo in Base Study: approximately Month 60 up to Month 120 ]An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose. Vaccine-related SAEs are those deemed by the investigator to be definitely, probably, or possibly related to study vaccine."},{"label":"4.","content":"Number of Participants With an SAE Resulting in Death After Vaccine Administration[ Time Frame: qHPV in Base Study: Up to Month 120; Placebo in Base Study: approximately Month 60 up to Month 120 ]An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or is an overdose."},{"label":"5.","content":"Cumulative Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN) or Condyloma: Day 1 to Year 4[ Time Frame: Up to Month 48 (up to 42 months after the third dose of qHPV vaccine in the Base Study) ]The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Day 1 to Year 4, conditional on having been event-free at Day 1."},{"label":"6.","content":"Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 4 to 8[ Time Frame: From 48 to 96 months (4 to 8 years) after the first dose of qHPV vaccine in the Base Study ]The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 4 to Year 8, conditional on having been event-free from Day 1 to Year 4. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval."},{"label":"7.","content":"Cumulative Incidence of HPV 6/11/16/18-related CIN or Condyloma: Year 6 to 10[ Time Frame: From 72 to 120 months (6 to 10 years) after the first dose of qHPV vaccine in the Base Study ]The four HPV types were determined by PCR testing. Cumulative incidence probability is the probability of becoming an endpoint case at any time from Year 6 to Year 10, conditional on having been event-free from Day 1 to Year 6."},{"label":"8.","content":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Day 1 to Year 4[ Time Frame: Up to Month 48 (up to 42 months after the third dose of qHPV vaccine in the Base Study) ]The four HPV types were determined by PCR testing."},{"label":"9.","content":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 4 to 8[ Time Frame: From 48 to 96 months (4 to 8 years) after the first dose of qHPV vaccine in the Base Study ]The four HPV types were determined by PCR testing. The analysis windows were cut at the exact time points, e.g., Year 4. Visits and events which occurred after Year 4 due to visit window or follow-up investigations are included in the Year 4 to Year 8 time interval."},{"label":"10.","content":"Incidence Rate of HPV 6/11/16/18-related CIN or Condyloma (Secondary Analysis): Year 6 to 10[ Time Frame: From 72 to 120 months (6 to 10 years) after the first dose of qHPV vaccine in the Base Study ]The four HPV types were determined by PCR testing."},{"label":"11.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 1 Month Postdose 3 in the Base Study[ Time Frame: Month 7 (1 month after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"12.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 6 Months Postdose 3 in the Base Study[ Time Frame: Month 12 (6 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"13.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 18 Months Postdose 3 in the Base Study[ Time Frame: Month 24 (18 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"14.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 30 Months Postdose 3 in the Base Study[ Time Frame: Month 36 (30 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"15.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 42 Months Postdose 3 in the Base Study[ Time Frame: Month 48 (42 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"16.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 66 Months Postdose 3 in the Base Study[ Time Frame: Month 72 (66 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"17.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 90 Months Postdose 3 in the Base Study[ Time Frame: Month 96 (90 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"18.","content":"Geometric Mean Titer for Anti-HPV Type 6, 11, 16, and 18 Antibody at 114 Months Postdose 3 in the Base Study[ Time Frame: Month 120 (114 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to the HPV Types were determined by Competitive Luminex Immunoassay (cLIA). Geometric Mean Titers (GMT) are reported in milli-Merck Units/mL (mMU/mL). This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"19.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 1 Month Postdose 3 in the Base Study[ Time Frame: Month 7 (1 month after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"20.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 6 Months Postdose 3 in the Base Study[ Time Frame: Month 12 (6 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"21.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 18 Months Postdose 3 in the Base Study[ Time Frame: Month 24 (18 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"22.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 30 Months Postdose 3 in the Base Study[ Time Frame: Month 36 (30 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"23.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 42 Months Postdose 3 in the Base Study[ Time Frame: Month 48 (42 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"24.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 66 Months Postdose 3 in the Base Study[ Time Frame: Month 72 (66 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"25.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 90 Months Postdose 3 in the Base Study[ Time Frame: Month 96 (96 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."},{"label":"26.","content":"Percentage of Participants Seropositive for Anti-HPV Antibody at 114 Months Postdose 3 in the Base Study[ Time Frame: Month 120 (114 months after the third dose of qHPV vaccine in the Base Study) ]Serum antibodies to HPV Types 6, 11, 16, and 18 were determined by Competitive Luminex Immunoassay (cLIA). The seropositive thresholds (in mMU/mL) were >20 for Type 6, >16 for Type 11, >20 for Type 16, and >24 for Type 18. This Outcome Measure evaluated age-specific immunogenicity responses, and applied only to participants who received qHPV in the Base Study."}],"start_date":"June 16, 2004","primary_completion_date":"May 21, 2009","completion_date":"November 12, 2015","first_posted":"August 27, 2004","results_first_posted":"February 1, 2010","last_update_posted":"April 21, 2017"},{"nctid":"NCT00083993","version_a":4,"version_b":5,"version_a_date":"2005-08-07","version_b_date":"2005-09-06","pom_a":[],"pom_b":[{"label":"1.","content":"To determine overall progression free survival."}],"start_date":"May 2004","primary_completion_date":"October 2006","completion_date":"October 2006","first_posted":"June 8, 2004","last_update_posted":"November 8, 2011"},{"nctid":"NCT02231164","version_a":30,"version_b":31,"version_a_date":"2016-04-26","version_b_date":"2016-12-20","pom_a":[{"label":"1.","content":"Progression free Survival[ Time Frame: up to 36 months ]"},{"label":"2.","content":"Overall Survival[ Time Frame: up to 36 months ]"}],"pom_b":[{"label":"1.","content":"Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1[ Time Frame: Up to 6 months. ]This outcome measure presents number of patients with disease control according to RECIST, version 1.1."}],"start_date":"October 2014","primary_completion_date":"December 2015","completion_date":"December 2015","first_posted":"September 4, 2014","results_first_posted":"February 13, 2017","last_update_posted":"March 21, 2017"},{"nctid":"NCT02231164","version_a":31,"version_b":32,"version_a_date":"2016-12-20","version_b_date":"2017-02-14","pom_a":[{"label":"1.","content":"Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1[ Time Frame: Up to 6 months. ]This outcome measure presents number of patients with disease control according to RECIST, version 1.1."}],"pom_b":[{"label":"1.","content":"Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1[ Time Frame: Up to 6 months. ]This outcome measure presents the number of patients with disease control according to RECIST, version 1.1, defined as number of patients with Complete response, partial response or stable disease."}],"start_date":"October 2014","primary_completion_date":"December 2015","completion_date":"December 2015","first_posted":"September 4, 2014","results_first_posted":"February 13, 2017","last_update_posted":"March 21, 2017"},{"nctid":"NCT00058188","version_a":7,"version_b":8,"version_a_date":"2006-11-08","version_b_date":"2006-12-06","pom_a":[],"pom_b":[{"label":"1.","content":"Bone density change as measured by dual-energy x-ray absorptiometry from baseline to13 months"}],"start_date":"March 2003","primary_completion_date":"November 2008","completion_date":"November 2008","first_posted":"April 9, 2003","results_first_posted":"November 19, 2020","last_update_posted":"December 8, 2020"},{"nctid":"NCT00058188","version_a":29,"version_b":30,"version_a_date":"2009-05-09","version_b_date":"2010-05-25","pom_a":[{"label":"1.","content":"Bone density change as measured by dual-energy x-ray absorptiometry from baseline to13 months"}],"pom_b":[{"label":"1.","content":"Bone density change as measured by dual-energy x-ray absorptiometry from baseline to 13 months[ Time Frame: Bone scan taken at baseline and month 13 ]To assess bone density change as measured by dual-energy x-ray absorptiometry"}],"start_date":"March 2003","primary_completion_date":"November 2008","completion_date":"November 2008","first_posted":"April 9, 2003","results_first_posted":"November 19, 2020","last_update_posted":"December 8, 2020"},{"nctid":"NCT00058188","version_a":40,"version_b":41,"version_a_date":"2019-05-01","version_b_date":"2020-10-23","pom_a":[{"label":"1.","content":"Bone density change as measured by dual-energy x-ray absorptiometry from baseline to 13 months[ Time Frame: Bone scan taken at baseline and month 13 ]To assess bone density change as measured by dual-energy x-ray absorptiometry"}],"pom_b":[{"label":"1.","content":"Bone Density Change as Measured by Dual-energy X-ray Absorptiometry From Baseline to 13 Months[ Time Frame: Bone scan taken at baseline and month 13 ]To assess bone density change as measured by dual-energy x-ray absorptiometry"}],"start_date":"March 2003","primary_completion_date":"November 2008","completion_date":"November 2008","first_posted":"April 9, 2003","results_first_posted":"November 19, 2020","last_update_posted":"December 8, 2020"},{"nctid":"NCT03106987","version_a":50,"version_b":51,"version_a_date":"2021-12-14","version_b_date":"2022-02-22","pom_a":[{"label":"1.","content":"Efficacy: Progression-free survival (PFS).[ Time Frame: At randomization visit and at every 12 weeks (+/- 7 days) until objective radiological disease progression as determined by the investigator or other discontinuation criteria are met. ]PFS measured from the date of randomisation to the date of investigator assessed disease progression (according to RECIST version 1.1 criteria) or death from any cause (in the absence of progression)."}],"pom_b":[{"label":"1.","content":"Efficacy: Progression-free Survival (PFS)[ Time Frame: At randomization visit and at every 12 weeks (+/- 7 days) until objective radiological disease progression as determined by the investigator or other discontinuation criteria are met (assessed upto 3.8 years) ]PFS was defined as the time from randomisation until the date of Investigator assessed objective radiological disease progression according to RECIST 1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to disease progression. Patients who have not progressed or died at the time of analysis was censored at the time of the latest date of assessment from their last evaluable RECIST assessment"}],"start_date":"June 8, 2017","primary_completion_date":"February 15, 2021","completion_date":"February 17, 2022","first_posted":"April 11, 2017","results_first_posted":"April 19, 2022","last_update_posted":"April 19, 2022"},{"nctid":"NCT00437749","version_a":2,"version_b":3,"version_a_date":"2007-09-11","version_b_date":"2008-04-24","pom_a":[{"label":"1.","content":"Overall Survival"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: every month for first 6 months off study, then every 2-3 months for the next year, then every 6 months thereafter ]"}],"start_date":"August 2001","primary_completion_date":"July 2010","completion_date":"November 2010","first_posted":"February 21, 2007","last_update_posted":"September 9, 2011"},{"nctid":"NCT02421939","version_a":15,"version_b":16,"version_a_date":"2017-08-23","version_b_date":"2017-10-31","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: up to 56 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: up to 30 months ]"},{"label":"2.","content":"Complete Remission and Complete Remission with partial hematological recovery (CR/CRh) rate[ Time Frame: up to 23 months ]"}],"start_date":"October 20, 2015","primary_completion_date":"September 17, 2018","completion_date":"July 31, 2023","first_posted":"April 21, 2015","results_first_posted":"October 17, 2019","last_update_posted":"September 13, 2022"},{"nctid":"NCT02421939","version_a":32,"version_b":33,"version_a_date":"2019-07-23","version_b_date":"2019-10-16","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: up to 30 months ]"},{"label":"2.","content":"Complete Remission and Complete Remission with partial hematological recovery (CR/CRh) rate[ Time Frame: up to 23 months ]"}],"pom_b":[{"label":"1.","content":"Duration of Overall Survival (OS)[ Time Frame: From randomization until the data cut-off date of 17 Sep 2018, median time of follow-up for OS was 17.8 months ]Overall survival was defined as the time from the date of randomization until the date of death from any cause (death date - randomization date + 1). For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - randomized date + 1). The date of last contact was the latest date that the participant was known to be alive by the cutoff date. The last contact date was derived for participants alive at the analysis cutoff date. Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula."},{"label":"2.","content":"Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm[ Time Frame: From randomization until the data cut-off date 04 Aug 2017, the 142 patients included in the primary analysis of CR/CRh rate were followed up at least 112 days ]The CR/CRh rate was defined as the number of participants who achieved either CR or CRh at any of the postbaseline visits divided by the number of participants in the analysis population."}],"start_date":"October 20, 2015","primary_completion_date":"September 17, 2018","completion_date":"July 31, 2023","first_posted":"April 21, 2015","results_first_posted":"October 17, 2019","last_update_posted":"September 13, 2022"},{"nctid":"NCT02735876","version_a":1,"version_b":2,"version_a_date":"2016-04-08","version_b_date":"2016-04-12","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) assessed by Independent Review Committee (IRC) per the Lugano Classification for Non-Hodgkin Lymphoma (NHL). The primary analysis is a comparison of PFS between Arm 1 and Arm 2.[ Time Frame: 48 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) assessed by Independent Review Committee (IRC) per the Lugano Classification for Non-Hodgkin Lymphoma (NHL). The primary analysis is a comparison of progression-free survival (PFS) between Arm 1 and Arm 2.[ Time Frame: 48 months ]"}],"start_date":"May 2016","primary_completion_date":"June 2020","first_posted":"April 13, 2016","last_update_posted":"May 13, 2016"},{"nctid":"NCT00006237","version_a":64,"version_b":65,"version_a_date":"2006-12-06","version_b_date":"2006-12-11","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival (OS) and disease-free survival (DFS)"},{"label":"2.","content":"Toxicity"},{"label":"3.","content":"Correlation of OS and DFS with number of involved lymph nodes, ulcerated primary, and extracapsular extension of minimal residual disease (MRD) as assessed by reverse-transcriptase polymerase chain reaction at baseline"},{"label":"4.","content":"MRD in peripheral blood at 12 and 52 weeks"},{"label":"5.","content":"Correlation of MRD status with OS at 12 and 52 weeks"}],"start_date":"August 2000","primary_completion_date":"July 2012","completion_date":"July 2012","first_posted":"January 27, 2003","results_first_posted":"September 19, 2012","last_update_posted":"March 25, 2015"},{"nctid":"NCT00006237","version_a":159,"version_b":160,"version_a_date":"2011-07-18","version_b_date":"2012-08-20","pom_a":[{"label":"1.","content":"Overall survival (OS) and disease-free survival (DFS)"},{"label":"2.","content":"Toxicity"},{"label":"3.","content":"Correlation of OS and DFS with number of involved lymph nodes, ulcerated primary, and extracapsular extension of minimal residual disease (MRD) as assessed by reverse-transcriptase polymerase chain reaction at baseline"},{"label":"4.","content":"MRD in peripheral blood at 12 and 52 weeks"},{"label":"5.","content":"Correlation of MRD status with OS at 12 and 52 weeks"}],"pom_b":[{"label":"1.","content":"5-year Overall Survival[ Time Frame: Every three months for a year, every six months for years 2-5, annual for years 5-10 ]Overall survival was measured from the date of registration to study until death from any cause with observations censored at the date of last contact for patients last known to be alive."},{"label":"2.","content":"5-year Relapse-Free Survival[ Time Frame: Every three months for the first year, every 6 months for years 2-5, annually for years 6-10 ]Measured from date of registration to date of first observation of progressive disease or death due to any cause."}],"start_date":"August 2000","primary_completion_date":"July 2012","completion_date":"July 2012","first_posted":"January 27, 2003","results_first_posted":"September 19, 2012","last_update_posted":"March 25, 2015"},{"nctid":"NCT02340221","version_a":35,"version_b":36,"version_a_date":"2016-11-01","version_b_date":"2017-05-15","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to approximately 3.5 years ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (v1.1)[ Time Frame: From randomization until the first occurence of disease progression or death from any cause, whichever occurs earlier (up to approximately 3.5 years) ]"}],"start_date":"April 9, 2015","primary_completion_date":"June 29, 2021","completion_date":"June 29, 2021","first_posted":"January 16, 2015","results_first_posted":"January 25, 2019","last_update_posted":"July 12, 2022"},{"nctid":"NCT02340221","version_a":46,"version_b":47,"version_a_date":"2018-06-15","version_b_date":"2019-01-22","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (v1.1)[ Time Frame: From randomization until the first occurence of disease progression or death from any cause, whichever occurs earlier (up to approximately 3.5 years) ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)[ Time Frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) ]PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression."}],"start_date":"April 9, 2015","primary_completion_date":"June 29, 2021","completion_date":"June 29, 2021","first_posted":"January 16, 2015","results_first_posted":"January 25, 2019","last_update_posted":"July 12, 2022"},{"nctid":"NCT02340221","version_a":63,"version_b":64,"version_a_date":"2022-01-19","version_b_date":"2022-07-11","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)[ Time Frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) ]PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis[ Time Frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years) ]PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression."},{"label":"2.","content":"PFS as Assessed by Investigator Using RECIST v1.1 at Final Analysis[ Time Frame: From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years) ]PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression."}],"start_date":"April 9, 2015","primary_completion_date":"June 29, 2021","completion_date":"June 29, 2021","first_posted":"January 16, 2015","results_first_posted":"January 25, 2019","last_update_posted":"July 12, 2022"},{"nctid":"NCT00305851","version_a":30,"version_b":31,"version_a_date":"2007-09-25","version_b_date":"2007-10-13","pom_a":[],"pom_b":[{"label":"1.","content":"Symptoms-related distress (pain, anxiety, fatigue, mucositis, sedation, and mood) at pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant"},{"label":"2.","content":"Uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale at baseline, immediately after completion of study treatment, and 100 days post-transplant"},{"label":"3.","content":"Use of defensive coping as assessed immediately after completion of study treatment, and 100 days post-transplant"},{"label":"4.","content":"Use of positive coping as assessed immediately after completion of study treatment, and 100 days post-transplant"}],"start_date":"April 15, 2006","primary_completion_date":"October 5, 2010","completion_date":"March 31, 2021","first_posted":"March 22, 2006","last_update_posted":"July 15, 2022"},{"nctid":"NCT00305851","version_a":86,"version_b":87,"version_a_date":"2012-04-12","version_b_date":"2014-02-12","pom_a":[{"label":"1.","content":"Symptoms-related distress (pain, anxiety, fatigue, mucositis, sedation, and mood) at pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant"},{"label":"2.","content":"Uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale at baseline, immediately after completion of study treatment, and 100 days post-transplant"},{"label":"3.","content":"Use of defensive coping as assessed immediately after completion of study treatment, and 100 days post-transplant"},{"label":"4.","content":"Use of positive coping as assessed immediately after completion of study treatment, and 100 days post-transplant"}],"pom_b":[{"label":"1.","content":"Symptoms-related distress (pain, anxiety, fatigue, mucositis, sedation, and mood)[ Time Frame: pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"2.","content":"Uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale[ Time Frame: baseline, immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"3.","content":"Use of defensive coping[ Time Frame: immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"4.","content":"Use of positive coping[ Time Frame: immediately after completion of study treatment, and 100 days post-transplant ]"}],"start_date":"April 15, 2006","primary_completion_date":"October 5, 2010","completion_date":"March 31, 2021","first_posted":"March 22, 2006","last_update_posted":"July 15, 2022"},{"nctid":"NCT00305851","version_a":90,"version_b":91,"version_a_date":"2016-02-19","version_b_date":"2022-07-13","pom_a":[{"label":"1.","content":"Symptoms-related distress (pain, anxiety, fatigue, mucositis, sedation, and mood)[ Time Frame: pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"2.","content":"Uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale[ Time Frame: baseline, immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"3.","content":"Use of defensive coping[ Time Frame: immediately after completion of study treatment, and 100 days post-transplant ]"},{"label":"4.","content":"Use of positive coping[ Time Frame: immediately after completion of study treatment, and 100 days post-transplant ]"}],"pom_b":[{"label":"1.","content":"Assess acute changes of Symptoms-related distress: Pain[ Time Frame: Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on pain. Specifically, the instrument includes a 1-item pain numeric rating scale."},{"label":"2.","content":"Assess acute changes of Symptoms-related distress: Anxiety[ Time Frame: Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on anxiety. Specifically, the instrument includes a 5-item Anxiety scale."},{"label":"3.","content":"Assess acute changes of Symptoms-related distress: Fatigue[ Time Frame: Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on fatigue. Specifically, the instrument includes a 1-item fatigue visual analogue scale."},{"label":"4.","content":"Assess acute changes of Symptoms-related distress: Mood[ Time Frame: Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant ]Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measures capturing information on mood. Specifically, the instrument includes a 1-item mood scale."},{"label":"5.","content":"Assess changes in uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale[ Time Frame: Change from baseline, immediately after completion of study treatment and 100 days post-transplant ]Mishel Uncertainty in Illness Scale-Revised (MUIS-R) consists of two factors: Complexity and Ambiguity, with higher scores indicating a high level of uncertainty. Item responses are on a 5-point Likert-type scale (ranging from 5 = Strongly Agree to 1 = Strongly Disagree"},{"label":"6.","content":"Assess changes in the use of defensive coping[ Time Frame: Change from immediately after completion of study treatment and 100 days post-transplant ]Defensive Coping will be measured by three subscales of the Jalowiec Coping Scale-Revised (JCS):evasive, emotive, and fatalistic coping. JCS is a self-report, 0-3 point rating scale. The items are scored for both use and effectiveness."},{"label":"7.","content":"Assess changes in the use of positive coping[ Time Frame: Change from immediately after completion of study treatment and 100 days post-transplant ]Three subscales of the Jalowiec Coping Scale-Revised will measure Positive Coping (JCS): confrontive, optimistic, and supportive."},{"label":"8.","content":"Assess changes in communication with family as assessed by Parent-Adolescent Communication[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Parent Adolescent Communication (P-AC) self-report items are on 5-point Likert scales that assess adolescents\' views regarding their perceptions and experience of communicating with each parent rated separately. The two subscales, Open Family Communication and Problems in Family Communication, respectively measure positive and negative aspects of communications within a family and are scored independently."},{"label":"9.","content":"Assess changes in adaptability or cohesion as assessed by FACES II[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Family Adaptability and Cohesion Scale II (FACES II) is a self-report scale using Likert response scales and measuring the 2 factors: Adaptability or cohesion"},{"label":"10.","content":"Assess changes in perceived social support from friends[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Perceived Social Support from Friends (PSS-Fr) is a self-report scale using 3-point rating responses ranging from 0 to 2 designed to measure the extent to which individuals perceive that their needs for support, information, and feedback are fulfilled by friends."},{"label":"11.","content":"Assess changes in perceived social support from family[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Perceived Social Support from Family (PSS-Fa) is a self-report, 3-point response (Yes, No, I don\'t know) scale, designed to measure the extent to which individuals perceive that their needs for support, information and feedback are fulfilled by family."},{"label":"12.","content":"Assess changes in perceived social support from healthcare providers[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Perceived Social Support from Health Care Providers (PSS-HCP) is a self-report, 3-point rating scale adapted by Haase from items on the Perceived Social Support-Friends scales102 to correspond to health care provider relationships. Items indicate the extent to which individuals perceive their needs for support, information, and feedback are fulfilled by health care providers."},{"label":"13.","content":"Assess changes in Hope from stem cell transplantation (STC) experience:[ Time Frame: Change from immediately after completion of study treatment, and 100 days post-transplant ]Measured by indicators of hope. Herth Hope Index (HHI) items are on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater hope."},{"label":"14.","content":"Assess changes in Spiritual Perspective from stem cell transplantation (STC) experience[ Time Frame: Change from immediately after completion of study treatment, and 100 days post-transplant ]Measured by indicators spiritual perspective. Reed Spiritual Perspective Scale (RSPS) is a one-factor scale that measures the saliency of spiritual beliefs and behaviors in the respondent\'s life.157 The response format is a 6-point Likert scale anchored with words describing the frequency of behaviors."},{"label":"15.","content":"Assess changes of Higher Resilience: Haase Adolescent Resilience in Cancer Scale[ Time Frame: Change from after completion of study treatment and 100 days post-transplant ]Haase Adolescent Resilience in Cancer Scale measures resilience related to illness. The scale uses a 6-point Likert-type scale ranging form: 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater resilience. Validity of the scales was found in predictive correlations with self-esteem, self-transcendence, confidence/mastery and quality of life. In Haase\'s preliminary studies, alpha reliability coefficients were 0.84 - 0.86."},{"label":"16.","content":"Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): NCS[ Time Frame: Change from after completion of study treatment, and 100 days post-transplant ]Nowotny Confidence Subscale (NCS) of the Nowotny Hope Scale is a self-report of confidence in one\'s own ability, which uses a 4-point Likert response format of strongly agree to strongly disagree"},{"label":"17.","content":"Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): STS[ Time Frame: Change from after completion of study treatment, and 100 days post-transplant ]Reed Self-Transcendence Scale (STS) assesses activities and perspectives individuals engage in to expand their boundaries via 4-point Likert response scales"},{"label":"18.","content":"Assess changes in Higher Resilience (self esteem, confidence, self-transcendence): SES[ Time Frame: Change from after completion of study treatment, and 100 days post-transplant ]Rosenberg Self-esteem Scale (SES) measures attitudes toward one\'s self. Responses are on a 4-point Likert scale."},{"label":"19.","content":"Assess changes in indicators of well-being and global quality of life: LASA Uniscale[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Measured by indicators of well-being and global quality of life.LASA Uniscale is a global QOL self-report one-item instrument: \\"Please score how you feel your life has been affected by the state of your health (any disease or treatment) during the last week\\".160 The item is adopted from the Southwest Oncology Group protocol, which adapted the scale from a linear analogue to categorical format with 5 response categories ranging from extremely unpleasant to normal (no change)."},{"label":"20.","content":"Assess changes in indicators of well-being and global quality of life: IWB[ Time Frame: Change from baseline, immediately after completion of study treatment, and 100 days post-transplant ]Measured by indicators of well-being and global quality of life. Index of Well-being (IWB) is a semantic differential scale describing present life using adjective extremes such as discouraging/hopeful."}],"start_date":"April 15, 2006","primary_completion_date":"October 5, 2010","completion_date":"March 31, 2021","first_posted":"March 22, 2006","last_update_posted":"July 15, 2022"},{"nctid":"NCT01517802","version_a":1,"version_b":2,"version_a_date":"2012-01-23","version_b_date":"2012-06-11","pom_a":[{"label":"1.","content":"The number of participants affected by a serious adverse event[ Time Frame: Up to 30 days after the last dose of study drug or early withdrawal ]"}],"pom_b":[{"label":"1.","content":"The number of participants affected by a serious adverse event[ Time Frame: Up to 30 days after the last dose of study drug ]"}],"start_date":"March 28, 2012","primary_completion_date":"April 22, 2021","completion_date":"April 22, 2021","first_posted":"January 25, 2012","results_first_posted":"May 10, 2022","last_update_posted":"May 10, 2022"},{"nctid":"NCT01517802","version_a":70,"version_b":71,"version_a_date":"2021-07-22","version_b_date":"2022-04-20","pom_a":[{"label":"1.","content":"The number of participants affected by a serious adverse event[ Time Frame: Up to 30 days after the last dose of study drug ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Serious Adverse Events (SAEs)[ Time Frame: Up to 9 years ]An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or is an important medical event."}],"start_date":"March 28, 2012","primary_completion_date":"April 22, 2021","completion_date":"April 22, 2021","first_posted":"January 25, 2012","results_first_posted":"May 10, 2022","last_update_posted":"May 10, 2022"},{"nctid":"NCT02302807","version_a":37,"version_b":38,"version_a_date":"2016-08-01","version_b_date":"2016-08-16","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Between randomization and death due to any cause, up to approximately 23 months after first patient enrolled ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled ]"}],"start_date":"January 13, 2015","primary_completion_date":"March 13, 2017","completion_date":"November 8, 2018","first_posted":"November 27, 2014","results_first_posted":"April 11, 2018","last_update_posted":"August 1, 2019"},{"nctid":"NCT02302807","version_a":46,"version_b":47,"version_a_date":"2017-12-11","version_b_date":"2018-03-13","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled ]OS was defined as time from randomization to death from any cause."}],"start_date":"January 13, 2015","primary_completion_date":"March 13, 2017","completion_date":"November 8, 2018","first_posted":"November 27, 2014","results_first_posted":"April 11, 2018","last_update_posted":"August 1, 2019"},{"nctid":"NCT04975997","version_a":4,"version_b":5,"version_a_date":"2021-11-18","version_b_date":"2022-04-21","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Approximately 3 years ]To compare the efficacy of iberdomide, daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in terms of progression-free survival (PFS) in participants with relapsed or refractory multiple myeloma (RRMM)."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Up to approximately 5 years ]To compare the efficacy of iberdomide, daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in terms of progression-free survival (PFS) in participants with relapsed or refractory multiple myeloma (RRMM)."}],"start_date":"June 23, 2022","primary_completion_date":"June 11, 2026","completion_date":"May 25, 2029","first_posted":"July 26, 2021","last_update_posted":"September 19, 2022"},{"nctid":"NCT00191477","version_a":4,"version_b":5,"version_a_date":"2007-10-18","version_b_date":"2007-12-20","pom_a":[{"label":"1.","content":"The primary objective of this study is to compare the efficacy of a postoperative intravesical instillation of gemcitabine"}],"pom_b":[{"label":"1.","content":"Recurrence free survival[ Time Frame: surgery to recurrence ]"}],"start_date":"January 2004","primary_completion_date":"March 2008","completion_date":"June 2008","first_posted":"September 19, 2005","results_first_posted":"October 28, 2009","last_update_posted":"October 28, 2009"},{"nctid":"NCT00191477","version_a":6,"version_b":7,"version_a_date":"2008-06-25","version_b_date":"2009-09-24","pom_a":[{"label":"1.","content":"Recurrence free survival[ Time Frame: surgery to recurrence ]"}],"pom_b":[{"label":"1.","content":"Recurrence-Free Survival (RFS)[ Time Frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months) ]Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression."}],"start_date":"January 2004","primary_completion_date":"March 2008","completion_date":"June 2008","first_posted":"September 19, 2005","results_first_posted":"October 28, 2009","last_update_posted":"October 28, 2009"},{"nctid":"NCT01387269","version_a":55,"version_b":56,"version_a_date":"2015-09-21","version_b_date":"2017-06-09","pom_a":[{"label":"1.","content":"Evaluate the effect of Anamorelin on lean body mass as measured by DXA scan[ Time Frame: 12 weeks ]"},{"label":"2.","content":"Evaluate the effect of Anamorelin on muscle strength as measured by hand-grip strength[ Time Frame: 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Change in Lean Body Mass[ Time Frame: Change in Lean Body Mass from Baseline Over 12 Weeks ]Change in Lean Body Mass (LBM) from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12."},{"label":"2.","content":"Change in Handgrip Strength[ Time Frame: Change in Handgrip Strength of the Non-Dominant Hand from Baseline Over 12 Weeks ]Change in Handgrip Strength (HGS) of the non-dominant hand from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12."}],"start_date":"July 2011","primary_completion_date":"January 2014","completion_date":"February 2015","first_posted":"July 4, 2011","results_first_posted":"July 11, 2017","last_update_posted":"October 27, 2017"},{"nctid":"NCT02544750","version_a":3,"version_b":4,"version_a_date":"2015-09-25","version_b_date":"2016-04-13","pom_a":[{"label":"1.","content":"Incidence of adverse events[ Time Frame: From OLE screening until market authorization is granted for GWP42003-P in TSC (anticipated to be 2 years after the OLE trial start date) ]The number of participants who experienced an adverse event during the trial is presented."}],"pom_b":[{"label":"1.","content":"Incidence of adverse events[ Time Frame: From OLE screening until market authorization is granted for GWP42003-P in TSC (anticipated to be 2 years after the OLE trial start date) ]"}],"start_date":"August 31, 2016","primary_completion_date":"June 11, 2021","completion_date":"June 11, 2021","first_posted":"September 9, 2015","results_first_posted":"July 14, 2022","last_update_posted":"July 14, 2022"},{"nctid":"NCT02544750","version_a":8,"version_b":9,"version_a_date":"2021-08-05","version_b_date":"2022-07-12","pom_a":[{"label":"1.","content":"Incidence of adverse events[ Time Frame: From OLE screening until market authorization is granted for GWP42003-P in TSC (anticipated to be 2 years after the OLE trial start date) ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)[ Time Frame: OLE Day 1 up to 4 years ]An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study."},{"label":"2.","content":"Number of Participants With Any TEAE, by Severity[ Time Frame: OLE Day 1 up to 4 years ]An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE.Grade 1 (Mild) is defined as asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate) is defined as minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL). Grade 3 (Severe) is defined as medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL."}],"start_date":"August 31, 2016","primary_completion_date":"June 11, 2021","completion_date":"June 11, 2021","first_posted":"September 9, 2015","results_first_posted":"July 14, 2022","last_update_posted":"July 14, 2022"},{"nctid":"NCT01017874","version_a":24,"version_b":25,"version_a_date":"2013-05-02","version_b_date":"2014-02-21","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: Every other cycle for 6 cycles then every 6 weeks from the date of randomization to the first date of measured progressive disease or death from any cause ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Randomization to the first date of measured PD or death up to 37.32 months ]PFS was defined as the time from date of randomization to the objective disease progression or death due to any cause. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.0) criteria. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions. Participants who did not have a complete baseline disease assessment were censored at the date of randomization, regardless if PD was objectively determined or if participant died or if a participant was not known to have died or have objective PD at the data inclusion cutoff date. PFS was censored at the last complete objective progression-free disease assessment date."}],"start_date":"November 2009","primary_completion_date":"April 2013","completion_date":"October 2014","first_posted":"November 23, 2009","results_first_posted":"April 3, 2014","last_update_posted":"July 8, 2015"},{"nctid":"NCT00004228","version_a":22,"version_b":23,"version_a_date":"2006-12-06","version_b_date":"2006-12-11","pom_a":[],"pom_b":[{"label":"1.","content":"Event-free survival as assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause"}],"start_date":"June 2000","primary_completion_date":"August 2008","completion_date":"March 31, 2015","first_posted":"January 27, 2003","results_first_posted":"December 5, 2013","last_update_posted":"August 6, 2019"},{"nctid":"NCT00004228","version_a":64,"version_b":65,"version_a_date":"2012-10-26","version_b_date":"2013-07-18","pom_a":[{"label":"1.","content":"Event-free survival as assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause"}],"pom_b":[{"label":"1.","content":"Event-free survival as assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause[ Time Frame: 4.3 years ]Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification."}],"start_date":"June 2000","primary_completion_date":"August 2008","completion_date":"March 31, 2015","first_posted":"January 27, 2003","results_first_posted":"December 5, 2013","last_update_posted":"August 6, 2019"},{"nctid":"NCT00004228","version_a":65,"version_b":66,"version_a_date":"2013-07-18","version_b_date":"2013-10-08","pom_a":[{"label":"1.","content":"Event-free survival as assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause[ Time Frame: 4.3 years ]Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification."}],"pom_b":[{"label":"1.","content":"Event-free Survival[ Time Frame: 5 years ]Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification."}],"start_date":"June 2000","primary_completion_date":"August 2008","completion_date":"March 31, 2015","first_posted":"January 27, 2003","results_first_posted":"December 5, 2013","last_update_posted":"August 6, 2019"},{"nctid":"NCT00362466","version_a":15,"version_b":16,"version_a_date":"2007-04-16","version_b_date":"2007-04-26","pom_a":[{"label":"1.","content":"Complete Cytogenetic Response rate at 6 months"}],"pom_b":[],"start_date":"April 2007","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"August 10, 2006","results_first_posted":"September 3, 2009","last_update_posted":"November 20, 2009"},{"nctid":"NCT00362466","version_a":16,"version_b":17,"version_a_date":"2007-04-26","version_b_date":"2007-04-28","pom_a":[],"pom_b":[{"label":"1.","content":"Complete Cytogenetic Response rate at 6 months"}],"start_date":"April 2007","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"August 10, 2006","results_first_posted":"September 3, 2009","last_update_posted":"November 20, 2009"},{"nctid":"NCT00362466","version_a":17,"version_b":18,"version_a_date":"2007-04-28","version_b_date":"2007-05-03","pom_a":[{"label":"1.","content":"Complete Cytogenetic Response rate at 6 months"}],"pom_b":[{"label":"1.","content":"Complete Cytogenetic Response rate[ Time Frame: at 6 months ]"}],"start_date":"April 2007","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"August 10, 2006","results_first_posted":"September 3, 2009","last_update_posted":"November 20, 2009"},{"nctid":"NCT00362466","version_a":57,"version_b":58,"version_a_date":"2008-07-21","version_b_date":"2009-07-24","pom_a":[{"label":"1.","content":"Complete Cytogenetic Response rate[ Time Frame: at 6 months ]"}],"pom_b":[{"label":"1.","content":"Complete Cytogenetic Response (CCyR) Rate at Month 6[ Time Frame: Month 6 ]Cytogenetic Response (CyR) is based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample. The criteria for CCyR is 0% Ph+ metaphases among cells in a bone marrow sample."}],"start_date":"April 2007","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"August 10, 2006","results_first_posted":"September 3, 2009","last_update_posted":"November 20, 2009"},{"nctid":"NCT00362466","version_a":58,"version_b":59,"version_a_date":"2009-07-24","version_b_date":"2009-11-18","pom_a":[{"label":"1.","content":"Complete Cytogenetic Response (CCyR) Rate at Month 6[ Time Frame: Month 6 ]Cytogenetic Response (CyR) is based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample. The criteria for CCyR is 0% Ph+ metaphases among cells in a bone marrow sample."}],"pom_b":[{"label":"1.","content":"Complete Cytogenetic Response (CCyR) Rate at Month 6[ Time Frame: Month 6 ]Cytogenetic Response (CyR) is based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample. The criteria for CCyR is 0% Ph+ metaphases among cells in a bone marrow sample."}],"start_date":"April 2007","primary_completion_date":"June 2008","completion_date":"June 2008","first_posted":"August 10, 2006","results_first_posted":"September 3, 2009","last_update_posted":"November 20, 2009"},{"nctid":"NCT00365989","version_a":7,"version_b":8,"version_a_date":"2012-09-11","version_b_date":"2012-09-13","pom_a":[{"label":"1.","content":"The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced."}],"pom_b":[{"label":"1.","content":"The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.[ Time Frame: Within 1 month of treatment ]"}],"start_date":"October 2006","primary_completion_date":"August 2008","completion_date":"August 2008","first_posted":"August 18, 2006","results_first_posted":"February 5, 2019","last_update_posted":"February 5, 2019"},{"nctid":"NCT00365989","version_a":9,"version_b":10,"version_a_date":"2018-03-26","version_b_date":"2019-02-04","pom_a":[{"label":"1.","content":"The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced.[ Time Frame: Within 1 month of treatment ]"}],"pom_b":[{"label":"1.","content":"Number of Adverse Events[ Time Frame: Within 1 month of treatment ]The study objective is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced."}],"start_date":"October 2006","primary_completion_date":"August 2008","completion_date":"August 2008","first_posted":"August 18, 2006","results_first_posted":"February 5, 2019","last_update_posted":"February 5, 2019"},{"nctid":"NCT00126789","version_a":1,"version_b":2,"version_a_date":"2005-08-02","version_b_date":"2005-08-18","pom_a":[{"label":"1.","content":"To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain."}],"pom_b":[{"label":"1.","content":"To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain"}],"start_date":"August 2005","primary_completion_date":"July 2007","completion_date":"July 2007","first_posted":"August 4, 2005","last_update_posted":"June 5, 2012"},{"nctid":"NCT00126789","version_a":6,"version_b":7,"version_a_date":"2008-01-03","version_b_date":"2012-06-04","pom_a":[{"label":"1.","content":"To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain"}],"pom_b":[{"label":"1.","content":"Number of participants with adverse events[ Time Frame: 12 weeks ]To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain"}],"start_date":"August 2005","primary_completion_date":"July 2007","completion_date":"July 2007","first_posted":"August 4, 2005","last_update_posted":"June 5, 2012"},{"nctid":"NCT00064038","version_a":50,"version_b":51,"version_a_date":"2006-10-25","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-free survival"}],"start_date":"November 2004","primary_completion_date":"October 2008","completion_date":"May 2012","first_posted":"July 9, 2003","results_first_posted":"July 17, 2013","last_update_posted":"March 25, 2015"},{"nctid":"NCT00064038","version_a":93,"version_b":94,"version_a_date":"2011-07-19","version_b_date":"2013-06-12","pom_a":[{"label":"1.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival[ Time Frame: From date of initial registration to date of progression/relapse of disease or death from any cause, whichever came first, up to 5 years ]Progression is defined as a > 25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc.In patients with a confirmed Partial Remission, Remission, or Complete Remission, relapse is defined as the first occurrence of any of the following: 1) a myeloma protein increase by than 100% from the lowest level recorded on study, provided the absolute magnitude of this increase is at least 1g/dL for a serum monoclonal protein or at least 500 mg/24 hrs of urine M-protein; 2) a myeloma protein increase above the response criteria for Partial Remission, with the same requirements for the absolute magnitude of the protein increase; 3)reappearance of any myeloma peak that had disappeared while on protocol treatment, provided it meets the same requirements listed above; 4) increase in the size and number of lytic bone lesions recognized on radiographs."}],"start_date":"November 2004","primary_completion_date":"October 2008","completion_date":"May 2012","first_posted":"July 9, 2003","results_first_posted":"July 17, 2013","last_update_posted":"March 25, 2015"},{"nctid":"NCT03570892","version_a":3,"version_b":4,"version_a_date":"2018-10-25","version_b_date":"2019-04-12","pom_a":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: 5 years ]Event-free survival (EFS) is defined as the time from the date of randomization to the date of the first documented disease progression or stable disease at or after the week 12 assessment, as assessed by Blinded Independent Review Committee (BIRC) per Lugano criteria, or death due to any cause, at any time."}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: 5 years ]Event-free survival (EFS) is defined as the time from the date of randomization to the date of the first documented disease progression or stable disease at or after the week 12 (+/- 1 week) assessment, as assessed by Blinded Independent Review Committee (BIRC) per Lugano criteria, or death due to any cause, at any time."}],"start_date":"May 7, 2019","primary_completion_date":"August 16, 2028","completion_date":"August 16, 2028","first_posted":"June 27, 2018","last_update_posted":"September 19, 2022"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,C.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,I.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var p="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:p,maxWidth:p}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,T.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,W.Z)(m.Z).breakpoints,s=H(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,f=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,y=s.direction,b=void 0===y?"row":y,g=s.item,_=void 0!==g&&g,k=s.rowSpacing,C=s.spacing,T=void 0===C?0:C,x=s.wrap,F=void 0===x?"wrap":x,P=s.zeroMinWidth,A=void 0!==P&&P,E=(0,w.Z)(s,oe),N=k||T,R=c||T,M=e.useContext(X),O=v?u||12:M,I={},z=(0,r.Z)({},E);i.keys.forEach((function(e){null!=E[e]&&(I[e]=E[e],delete z[e])}));var D=(0,r.Z)({},s,{columns:O,container:v,direction:b,item:_,rowSpacing:N,columnSpacing:R,wrap:F,zeroMinWidth:A,spacing:T},I,{breakpoints:i.keys}),L=ue(D);return(0,p.jsx)(X.Provider,{value:O,children:(0,p.jsx)(le,(0,r.Z)({ownerState:D,className:(0,S.Z)(L.root,l),as:f,ref:n},z))})})),de=ce,pe=n(2065);function fe(e){return(0,C.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,I.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,pe.Fq)("#fff",he(a.elevation)),", ").concat((0,pe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),ye=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,f=n.variant,m=void 0===f?"elevation":f,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),y=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,T.Z)(o,fe,a)}(v);return(0,p.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(y.root,o),ref:t},h))}));function be(e){return(0,C.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,I.ZP)(ye,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},be,t)}(u);return(0,p.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,C.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var ke=["className","component"],Ce=(0,I.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Te=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,ke),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},Se,t)}(u);return(0,p.jsx)(Ce,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function xe(e){return(0,C.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var Fe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Pe=(0,I.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,O.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ae={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Ee={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ne=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Ee[e]||e}(n.color),i=H((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,f=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,y=void 0!==v&&v,b=i.variant,g=void 0===b?"body1":b,_=i.variantMapping,k=void 0===_?Ae:_,C=(0,w.Z)(i,Fe),x=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:f,noWrap:h,paragraph:y,variant:g,variantMapping:k}),F=c||(y?"p":k[g]||Ae[g])||"span",P=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,O.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,T.Z)(s,xe,i)}(x);return(0,p.jsx)(Pe,(0,r.Z)({as:F,ref:t,ownerState:x,className:(0,S.Z)(P.root,u)},C))})),Re=n(5682),Me=["component","direction","spacing","divider","children"];function Oe(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Ie=(0,I.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Re.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Re.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),ze=e.forwardRef((function(e,t){var n=H((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,f=n.children,m=(0,w.Z)(n,Me),h={direction:l,spacing:c};return(0,p.jsx)(Ie,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Oe(f,d):f}))})),De=ze,Le=n(1774),Ze=n.n(Le);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,p.jsx)(we,{children:(0,p.jsx)(Te,{children:(0,p.jsxs)(Ne,{children:[(0,p.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,p.jsxs)(de,{container:!0,spacing:2,children:[(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsx)(Te,{children:(0,p.jsxs)(de,{container:!0,children:[(0,p.jsxs)(de,{item:!0,xs:4,children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,p.jsxs)(Ne,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,p.jsxs)(Ne,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,p.jsxs)(Ne,{children:["Start Date: ",t.start_date]}):null]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,p.jsxs)(Ne,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,p.jsxs)(Ne,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,p.jsx)(Ne,{variant:"caption"}),(0,p.jsx)(De,{spacing:1,children:l(t.pom_a)})]})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsxs)(Ne,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,p.jsx)(De,{spacing:1,children:l(t.pom_b)})]})})}),(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsx)(Ne,{variant:"h6",children:"Compare the Raw Text"}),(0,p.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,C.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var Ve=["className","color","enableColorOnDark","position"],Ue=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},He=(0,I.ZP)(ye,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,O.Z)(n.position))],t["color".concat((0,O.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),We=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,f=(0,w.Z)(n,Ve),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,O.Z)(t)),"position".concat((0,O.Z)(n))]};return(0,T.Z)(a,Be,r)}(m);return(0,p.jsx)(He,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},f))}));function Je(e){return(0,C.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],Ge=(0,I.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,f=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,T.Z)(n,Je,t)}(m);return(0,p.jsx)(Ge,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},f))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,f=e.useState(!1),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),b={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,p.jsx)("span",{className:y,style:b,children:(0,p.jsx)("span",{className:_})})};var ut,ct,dt,pt,ft,mt,ht,vt,yt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),bt=["center","classes","className"],gt=d(ft||(ft=ut||(ut=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,I.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),kt=(0,I.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=pt||(pt=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),yt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),yt.child,yt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Ct=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,bt),f=e.useState([]),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=e.useRef(0),b=e.useRef(null);e.useEffect((function(){b.current&&(b.current(),b.current=null)}),[h]);var _=e.useRef(!1),k=e.useRef(null),C=e.useRef(null),T=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(k.current)}}),[]);var x=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,p.jsx)(kt,{classes:{ripple:(0,S.Z)(u.ripple,yt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,yt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,yt.ripplePulsate),child:(0,S.Z)(u.child,yt.child),childLeaving:(0,S.Z)(u.childLeaving,yt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,yt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},y.current)])})),y.current+=1,b.current=o}),[u]),F=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,p,f=u?null:T.current,m=f?f.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,y=h.clientY;c=Math.round(v-m.left),d=Math.round(y-m.top)}if(i)(p=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(p+=1);else{var b=2*Math.max(Math.abs((f?f.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((f?f.clientHeight:0)-d),d)+2;p=Math.sqrt(Math.pow(b,2)+Math.pow(g,2))}null!=e&&e.touches?null===C.current&&(C.current=function(){x({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})},k.current=setTimeout((function(){C.current&&(C.current(),C.current=null)}),80)):x({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})}}),[s,x]),P=e.useCallback((function(){F({},{pulsate:!0})}),[F]),A=e.useCallback((function(e,t){if(clearTimeout(k.current),"touchend"===(null==e?void 0:e.type)&&C.current)return C.current(),C.current=null,void(k.current=setTimeout((function(){A(e,t)})));C.current=null,v((function(e){return e.length>0?e.slice(1):e})),b.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:P,start:F,stop:A}}),[P,F,A]),(0,p.jsx)(St,(0,r.Z)({className:(0,S.Z)(yt.root,u.root,c),ref:T},d,{children:(0,p.jsx)(st,{component:null,exit:!0,children:h})}))})),Tt=Ct;function xt(e){return(0,C.Z)("MuiButtonBase",e)}var Ft,Pt=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),At=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Et=(0,I.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((Ft={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(Ft,"&.".concat(Pt.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(Ft,"@media print",{colorAdjust:"exact"}),Ft)),Nt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,f=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,y=void 0!==v&&v,b=o.disableTouchRipple,_=void 0!==b&&b,k=o.focusRipple,C=void 0!==k&&k,x=o.LinkComponent,F=void 0===x?"a":x,P=o.onBlur,A=o.onClick,E=o.onContextMenu,N=o.onDragLeave,R=o.onFocus,M=o.onFocusVisible,O=o.onKeyDown,I=o.onKeyUp,z=o.onMouseDown,D=o.onMouseLeave,L=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,B=o.onTouchStart,V=o.tabIndex,U=void 0===V?0:V,H=o.TouchRippleProps,W=o.touchRippleRef,J=o.type,$=(0,w.Z)(o,At),G=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,W),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),G.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!y&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&C&&!y&&le&&q.current.pulsate()}),[y,C,ae,le]);var pe=de("start",z),fe=de("stop",E),me=de("stop",N),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),D&&D(e)})),ye=de("start",B),be=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),P&&P(e)}),!1),we=(0,Qe.Z)((function(e){G.current||(G.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),M&&M(e)),R&&R(e)})),Se=function(){var e=G.current;return f&&"button"!==f&&!("A"===e.tagName&&e.href)},ke=e.useRef(!1),Ce=(0,Qe.Z)((function(e){C&&!ke.current&&ae&&q.current&&" "===e.key&&(ke.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),O&&O(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),A&&A(e))})),Te=(0,Qe.Z)((function(e){C&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(ke.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),I&&I(e),A&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&A(e)})),xe=f;"button"===xe&&($.href||$.to)&&(xe=F);var Fe={};"button"===xe?(Fe.type=void 0===J?"button":J,Fe.disabled=h):($.href||$.to||(Fe.role="button"),h&&(Fe["aria-disabled"]=h));var Pe=(0,Ke.Z)(te,G),Ae=(0,Ke.Z)(n,Pe);var Ee=(0,r.Z)({},o,{centerRipple:l,component:f,disabled:h,disableRipple:y,disableTouchRipple:_,focusRipple:C,tabIndex:U,focusVisible:ae}),Ne=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,T.Z)(o,xt,a);return n&&r&&(i.root+=" ".concat(r)),i}(Ee);return(0,p.jsxs)(Et,(0,r.Z)({as:xe,className:(0,S.Z)(Ne.root,c),ownerState:Ee,onBlur:_e,onClick:A,onContextMenu:fe,onFocus:we,onKeyDown:Ce,onKeyUp:Te,onMouseDown:pe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:be,onTouchMove:ge,onTouchStart:ye,ref:Ae,tabIndex:h?-1:U,type:J},Fe,$,{children:[u,ce?(0,p.jsx)(Tt,(0,r.Z)({ref:K,center:l},H)):null]}))})),Rt=Nt;function Mt(e){return(0,C.Z)("MuiIconButton",e)}var Ot=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),It=["edge","children","className","color","disabled","disableFocusRipple","size"],zt=(0,I.ZP)(Rt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,O.Z)(n.color))],n.edge&&t["edge".concat((0,O.Z)(n.edge))],t["size".concat((0,O.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Ot.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),Dt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,f=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,y=void 0===v?"medium":v,b=(0,w.Z)(n,It),g=(0,r.Z)({},n,{edge:i,color:c,disabled:f,disableFocusRipple:h,size:y}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,O.Z)(r)),a&&"edge".concat((0,O.Z)(a)),"size".concat((0,O.Z)(o))]};return(0,T.Z)(i,Mt,t)}(g);return(0,p.jsx)(zt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:f,ref:t,ownerState:g},b,{children:s}))})),Lt=n(2156),Zt=n(5129);n(8472),(0,G.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,p.jsx)(K,{sx:{flexGrow:1},children:(0,p.jsx)(We,{position:"static",children:(0,p.jsxs)(qe,{children:[(0,p.jsxs)(Ne,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,p.jsxs)(Ne,{component:"div",children:[t>0?(0,p.jsx)(Dt,{color:"inherit",variant:"text",onClick:o,children:(0,p.jsx)(Lt.Z,{})}):null,t<r-1?(0,p.jsx)(Dt,{color:"inherit",variant:"text",onClick:i,children:(0,p.jsx)(Zt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Vt=[],Ut=Q.e,Ht=Q.C,Wt=Ht.length,Jt=0;Jt<Wt;Jt++)Vt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Ht[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Vt),c=(0,g.Z)(u,2),d=c[0],f=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],y=h[1];return(0,e.useEffect)((function(){l(Ht[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Wt;t++){var n={};n.nctid=Ht[t].nctid,n.version_a=Ht[t].version_a,n.version_b=Ht[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}y(e)}),[d]),(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Wt,outputData:v,batchNum:Ut}),(0,p.jsx)(D,{children:(0,p.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,p.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:f})})})]})};t.createRoot(document.getElementById("root")).render((0,p.jsxs)(e.StrictMode,{children:[(0,p.jsx)(b,{}),(0,p.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.18db2dfc.js.map